Beta-lactam & Beta-lactamase Inhibitors Market
Beta-lactam and Beta-lactamase Inhibitors Market by type (Individual Beta-lactum Antibiotics, and Beta-lactum/Beta-lactamase Inhibitor Combination), by Route of Administration (Oral Administration, Parental Administration and Other Routes), by Patient Type (Adult Patients and Pediatric Patients), by Application/Indication (Gynecological Infections, Intrabdominal Infections, Intraoperative Prophylaxis, and others), and by End User - Global Opportunity Analysis and Industry Forecast, 2020 – 2030
Industry: Healthcare | Publish Date: 18-Jun-2025 | No of Pages: 580 | No. of Tables: 375 | No. of Figures: 304 | Format: PDF | Report Code : HC54
Market Definition
At an estimated value of over 27.49 billion USD in 2019, the global Beta-lactam and Beta-lactamase market is predicted to thrive at a CAGR of 1.9% and valued at over USD 34.20 billion over the forecast year 2020-2030.
Beta-lactam inhibitors fall under a class of antibiotics that consists of all antibiotic agents that have a beta lactam ring embedded in their molecular structure. These antibiotic agents helps fight against bacterial infections and protozoa infections. The antibiotic agent either completely kills the bacteria or prevents it from growing and expanding. Names of some beta-lactam antibiotics are penicillin, cephalosporin and many others. On the other hand, beta-lactamase inhibitors are a class of drugs that block the activity of beta-lactamase enzymes and restricts the degradation of beta-lactam. Beta-lactamase enzymes are created either constitutively or on exposure to antimicrobials.
Market Dynamics and Trends
The widespread presence of infectious diseases along with the growth in consumption of identical drugs in developing countries indicate the growth of beta-lactam and beta-lactamase inhibitors market. Recent improvements in the healthcare sector and advancement of medical technology have further contributed to this market growth. The surge in number of clinical trials of such drugs have further augmented the growth of the market. However, evolution of antibiotic resistance and misuse due to over the counter availability are expected to impede the growth of beta-lactam and beta-lactamase Inhibitors market. Contradictorily, discovery of advanced prospect molecules and novel combination therapies are anticipated to offer significant opportunities to the market players and hence increase their beta-lactam and beta-lactamase inhibitors market share.
Market Segmentations and Scope of the Study
The global beta-lactam and beta-lactamase inhibitors market share has been segmented on the basis of type, route of administration, patient type, application/indication (disease level) and end user (healthcare setting). On the basis of type, the market is categorized into individual beta-lactum antibiotics and beta-lactum/beta-lactamase inhibitor combination. On the basis of route of administration, the market is segmented into oral administration, parental administration and other routes. On the basis of patient type, the market is segmented into adult patients and pediatric patients. On the basis of application/indication (disease level), the market is segmented into gynecological infections, intrabdominal infections, intraoperative prophylaxis,respiratory infections, skin and soft tissue infections (SSTI), urinary tract infections (UTI), bloodstream infections (BSI) and other infections. On the basis of end user (heathcare setting), the market is segmented into academic institutions, clinics, hospitals and research laboratories.in terms of geography, the market is categorized into North America, Europe, Asia Pacific and RoW.
Geographical Analysis
The North America region is anticipated to hold the major market share as a result of advanced health care facilities and infrastructure in conjunction with rise in acceptance of beta-lactam and beta-lactamase inhibitors.
The Asia Pacific region is predicted to show rapid and consistent growth in market share within the forecast period. This region also indicates increased prevalence of infectious diseases in addition to rise in consumption of such drugs, which also serves as favorable factor for the beta-lactam and beta-lactamase inhibitor market.
Competitive Landscape
Lucrative growth opportunities makes the Beta-lactam and Beta-lactamase inhibitors market extremely competitive. Some of the major players in the market include Alkem Laboratories Ltd., Aurobindo Pharma, Cipla Inc., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Ltd., Meiji Holdings Co. Ltd., Merck & Co. Inc., Pfizer Inc., Sandoz International GmbH (Novartis), Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Ltd.,Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris (formerly Mylan N.V.), Zeelab Laboratories Ltd., Zentiva Group B.V., Zydus Lifesciences Limited (Cadila Healthcare) and others. A number of developmental strategies have been adopted by companies in the recent years to further promote the growth of the market.
Key Benefits
-
The Beta-lactam and Beta-lactamase Inhibitor market report provides the quantitative analysis of the current market and estimations through 2020-2030 that assists in identifying the prevailing market opportunities to capitalize on
-
The study comprises a deep dive analysis of the Beta-lactam and Beta-lactamase Inhibitor market trend including the current and future trends for depicting the prevalent investment pockets in the market
-
The information related to key drivers, restraints and opportunities and their impact on the Beta-lactam and Beta-Lactamase Inhibitor market is provided in the report.
-
The market share of the players in the global Beta-lactam and Beta-lactamase Inhibitor market along with their competitive analysis.
-
Value chain analysis in the market study provides a clear picture of the stakeholders’ roles
Key Market Segments
By Type
-
Individual Beta-lactam Antibiotics
-
Penicillins
-
Natural Penicillins
-
Aminopenicillins
-
Extended-Spectrum Penicillins
-
-
Cephalosporins
-
First-Generation
-
Second-Generation
-
Third-Generation
-
Fourth-Generation
-
Fifth-Generation
-
-
Carbapenems
-
Doripenem
-
Ertapenem
-
Imipenem
-
Meropenem
-
-
Monobactams
-
-
Beta-lactam/Beta-lactamase Inhibitor Combinations
-
Penicillin Combinations
-
Amoxicillin-clavulanate
-
Ampicillin-sulbactam
-
Piperacillin-tazobactam
-
Ticarcillin-clavulanate
-
-
Cephalosporin Combinations
-
Ceftazidime-avibactam
-
Cefepime-tazobactam
-
-
Carbapenem Combinations
-
Meropenem-vaborbactam
-
Imipenem-relebactam
-
-
Others
-
By Route of Administration
-
Oral Administration
-
Capsules
-
Tablets
-
-
Parenteral Administration
-
Intramuscular Injection (IM)
-
Intravenous Infusion/Injection (IV)
-
-
Other Routes
By Patient Type
-
Adult Patients
-
Young Adults (18–40 years)
-
Middle-Aged Adults (41–64 years)
-
Senior Adults (≥ 65 years)
-
-
Pediatric Patients
-
Adolescents (12–17 years)
-
Children (2–11 years)
-
Infants (1 month–1 year)
-
Neonates (≤ 1 month)
-
By Application/Indication (Disease Level)
-
Gynecological Infections
-
Pelvic Inflammatory Disease (PID)
-
Bacterial Vaginosis (if treated with β-lactam)
-
Other Female-Reproductive-Tract Infections
-
-
Intrabdominal Infections
-
Uncomplicated Intra-Abdominal Infection
-
-
Intraoperative Prophylaxis
-
Respiratory Infections
-
Complicated Intra-Abdominal Infection
-
Nosocomial Pneumonia
-
Hospital-Acquired Pneumonia (HAP)
-
Ventilator-Associated Pneumonia (VAP)
-
Other Nosocomial Pneumonia
-
-
-
Skin and Soft Tissue Infections (SSTI)
-
Cellulitis
-
Erysipelas
-
Impetigo
-
Other SSTIs
-
-
Urinary Tract Infections (UTI)
-
Acute Uncomplicated UTI
-
Chronic/Recurrent UTI
-
Complicated UTI
-
-
Bloodstream Infections (BSI)
-
Other Infections
-
Meningitis
-
Osteomyelitis
-
Endocarditis
-
Other Rare/Off-Label Uses
-
By End User (Healthcare Setting)
-
Academic Institutions
-
Clinics
-
Hospitals
-
Research Laboratories
By Geography
-
North America
-
Canada
-
U.S.
-
Mexico
-
-
Europe
-
Germany
-
France
-
Spain
-
Italy
-
UK
-
Rest of Europe
-
-
Asia-Pacific
-
Japan
-
India
-
China
-
South Korea
-
Indonesia
-
Thailand
-
Vietnam
-
Taiwan
-
Rest of Asia-Pacific
-
-
RoW
-
Saudi Arabia
-
Brazil
-
Remaining Countries
-
Key Players:
-
Alkem Laboratories Ltd.
-
Aurobindo Pharma
-
Cipla Inc.
-
Dr. Reddy’s Laboratories Ltd.
-
GlaxoSmithKline PLC
-
Hikma Pharmaceuticals PLC
-
Lupin Ltd.
-
Meiji Holdings Co. Ltd.
-
Merck & Co. Inc.
-
Pfizer Inc.
-
Sandoz International GmbH (Novartis)
-
Shionogi & Co., Ltd.
-
Sun Pharmaceutical Industries Ltd.
-
Taj Pharmaceuticals Ltd.
-
Teva Pharmaceutical Industries Ltd.
-
Torrent Pharmaceuticals Ltd.
-
Viatris (formerly Mylan N.V.)
-
Zeelab Laboratories Ltd.
-
Zentiva Group B.V.
-
Zydus Lifesciences Limited (Cadila Healthcare)
REPORT SCOPE AND SEGMENTATION:
|
Parameters |
Details |
|
Analysis Period |
2019–2030 |
|
Base Year Considered |
2020 |
|
Forecast Period |
2020–2030 |
|
Market Size Estimation |
Billion (USD) |
|
Market Segmentation |
Beta-lactam and Beta-lactamase Inhibitors Market by type (Individual Beta-lactum Antibiotics, and Beta-lactum/Beta-lactamase Inhibitor Combination), by Route of Administration (Oral Administration, Parental Administration and Other Routes), by Patient Type (Adult Patients and Pediatric Patients), by Application/Indication (Gynecological Infections, Intrabdominal Infections, Intraoperative Prophylaxis, Respiratory Infections, Skin and Soft Tissue Infections (SSTI), Urinary Tract Infections (UTI), Bloodstream Infections (BSI), and Other Infections), and By End User (Healthcare Setting) |
|
Geographical Segmentation |
North America (U.S., Canada, Mexico) Europe (Germany, UK, Spain, France, Italy, Rest of Europe), Asia-Pacific (Indonesia, China, India, Japan, South Korea, Thailand, Vietnam, Taiwan, Rest of APAC) Rest of World (Brazil, Saudi Arabia, Remaining Countries) |
|
Companies Profiled |
Alkem Laboratories Ltd., Aurobindo Pharma, Cipla Inc., Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Lupin Ltd., Meiji Holdings Co. Ltd., Merck & Co. Inc., Pfizer Inc., Sandoz International GmbH (Novartis), Shionogi & Co., Ltd., Sun Pharmaceutical Industries Ltd., Taj Pharmaceuticals Ltd.,Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Viatris (formerly Mylan N.V.), Zeelab Laboratories Ltd., Zentiva Group B.V., Zydus Lifesciences Limited (Cadila Healthcare) |
1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2 BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET – EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD
3 PORTER’S FIVE FORCE MODEL ANALYSIS
3.1 BARGAINING POWER OF SUPPLIERS
3.2 BARGAINING POWER OF BUYERS
3.3 DEGREE OF COMPETITION
3.4 THREAT OF SUBSTITUTE
3.5 THREAT OF NEW ENTRANTS
4 MARKET SHARE ANALYSIS
4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024
5 MARKET DYNAMICS
5.1 GROWTH DRIVERS
5.1.1 DRIVER 1
5.1.2 DRIVER 2
5.1.3 DRIVER 3
5.1.4 DRIVER 4
5.2 CHALLENGES
5.2.1 CHALLENGE 1
5.2.2 CHALLENGE 2
5.2.3 CHALLENGE 3
5.2.4 CHALLENGE 4
5.3 OPPORTUNITIES
5.3.1 OPPORTUNITY 1
5.3.2 OPPORTUNITY 2
6 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY TYPE
6.1 OVERVIEW
6.2 INDIVIDUAL BETA-LACTAM ANTIBIOTICS
6.2.1 GLOBAL INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
6.2.1.1 PENICILLINS MARKET, BY REGION
6.2.1.1.1 NATURAL PENICILLINS
6.2.1.1.2 AMINOPENICILLINS
6.2.1.1.3 EXTENDED-SPECTRUM PENICILLINS
6.2.1.1.1.1 NORTH AMERICA PENICILLINS MARKET, BY COUNTRY
6.2.1.1.1.2 EUROPE PENICILLINS MARKET, BY COUNTRY
6.2.1.1.1.3 ASIA-PACIFIC PENICILLINS MARKET, BY COUNTRY
6.2.1.1.1.4 REST OF THE WORLD PENICILLINS MARKET, BY COUNTRY
6.2.1.2 CEPHALOSPORINS MARKET, BY REGION
6.2.1.2.1 FIRST-GENERATION
6.2.1.2.2 SECOND-GENERATION
6.2.1.2.3 THIRD-GENERATION
6.2.1.2.4 FOURTH-GENERATION
6.2.1.2.5 FIFTH-GENERATION
6.2.1.2.1.1 NORTH AMERICA CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.2.1.2 EUROPE CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.2.1.3 ASIA-PACIFIC CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.2.1.4 REST OF THE WORLD CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.3 CARBAPENEMS MARKET, BY REGION
6.2.1.3.1 DORIPENEM
6.2.1.3.2 ERTAPENEM
6.2.1.3.3 IMIPENEM
6.2.1.3.4 MEROPENEM
6.2.1.3.1.1 NORTH AMERICA CARBAPENEMS MARKET, BY COUNTRY
6.2.1.3.1.2 EUROPE CARBAPENEMS MARKET, BY COUNTRY
6.2.1.3.1.3 ASIA-PACIFIC CARBAPENEMS MARKET, BY COUNTRY
6.2.1.3.1.4 REST OF THE WORLD CARBAPENEMS MARKET, BY COUNTRY
6.2.1.4 MONOBACTAMS MARKET, BY REGION
6.2.1.4.1 NORTH AMERICA MONOBACTAMS MARKET, BY COUNTRY
6.2.1.4.2 EUROPE MONOBACTAMS MARKET, BY COUNTRY
6.2.1.4.3 ASIA-PACIFIC MONOBACTAMS MARKET, BY COUNTRY
6.2.1.4.4 REST OF THE WORLD MONOBACTAMS MARKET, BY COUNTRY
6.2.2 INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY REGION
6.2.2.1 NORTH AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.2.2.2 EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.2.2.3 ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.2.2.4 REST OF THE WORLD INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.3 BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS
6.3.1 GLOBAL BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
6.3.1.1 PENICILLIN COMBINATIONS MARKET, BY REGION
6.3.1.1.1 AMOXICILLIN-CLAVULANATE
6.3.1.1.2 AMPICILLIN-SULBACTAM
6.3.1.1.3 PIPERACILLIN-TAZOBACTAM
6.3.1.1.4 TICARCILLIN-CLAVULANATE
6.3.1.1.1.1 NORTH AMERICA PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.1.1.2 EUROPE PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.1.1.3 ASIA-PACIFIC PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.1.1.4 REST OF THE WORLD PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2 CEPHALOSPORIN COMBINATIONS MARKET, BY REGION
6.3.1.2.1 CEFTAZIDIME-AVIBACTAM
6.3.1.2.2 CEFEPIME-TAZOBACTAM
6.3.1.2.1 NORTH AMERICA CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2.2 EUROPE CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2.3 ASIA-PACIFIC CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2.4 REST OF THE WORLD CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.3 CARBAPENEM COMBINATIONS MARKET, BY REGION
6.3.1.3.1 MEROPENEM-VABORBACTAM
6.3.1.3.2 IMIPENEM-RELEBACTAM
6.3.1.3.1.1 NORTH AMERICA CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.3.1.2 EUROPE CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.3.1.3 ASIA-PACIFIC CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.3.1.4 REST OF THE WORLD CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.4 OTHERS MARKET, BY REGION
6.3.1.4.1 NORTH AMERICA OTHERS MARKET, BY COUNTRY
6.3.1.4.2 EUROPE OTHERS MARKET, BY COUNTRY
6.3.1.4.3 ASIA-PACIFIC OTHERS MARKET, BY COUNTRY
6.3.1.4.4 REST OF THE WORLD OTHERS MARKET, BY COUNTRY
6.3.2 BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY REGION
6.3.2.1 NORTH AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
6.3.2.2 EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
6.3.2.3 ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
6.3.2.4 REST OF THE WORLD BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
7 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL ADMINISTRATION
7.2.1 GLOBAL ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
7.2.1.1 CAPSULES MARKET, BY REGION
7.2.1.1.1 NORTH AMERICA CAPSULES MARKET, BY COUNTRY
7.2.1.1.2 EUROPE CAPSULES MARKET, BY COUNTRY
7.2.1.1.3 ASIA-PACIFIC CAPSULES MARKET, BY COUNTRY
7.2.1.1.4 REST OF THE WORLD CAPSULES MARKET, BY COUNTRY
7.2.1.2 TABLETS MARKET, BY REGION
7.2.1.2.1 NORTH AMERICA TABLETS MARKET, BY COUNTRY
7.2.1.2.2 EUROPE TABLETS MARKET, BY COUNTRY
7.2.1.2.3 ASIA-PACIFIC TABLETS MARKET, BY COUNTRY
7.2.1.2.4 REST OF THE WORLD TABLETS MARKET, BY COUNTRY
7.2.2 ORAL ADMINISTRATION MARKET, BY REGION
7.2.2.1 NORTH AMERICA ORAL ADMINISTRATION MARKET, BY COUNTRY
7.2.2.2 EUROPE ORAL ADMINISTRATION MARKET, BY COUNTRY
7.2.2.3 ASIA-PACIFIC ORAL ADMINISTRATION MARKET, BY COUNTRY
7.2.2.4 REST OF THE WORLD ORAL ADMINISTRATION MARKET, BY COUNTRY
7.3 PARENTERAL ADMINISTRATION
7.3.1 GLOBAL PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
7.3.1.1 INTRAMUSCULAR INJECTION (IM) MARKET, BY REGION
7.3.1.1.1 NORTH AMERICA INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.1.2 EUROPE INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.1.3 ASIA-PACIFIC INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.1.4 REST OF THE WORLD INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.2 INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY REGION
7.3.1.2.1 NORTH AMERICA INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.1.2.2 EUROPE INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.1.2.3 ASIA-PACIFIC INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.1.2.4 REST OF THE WORLD INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.2 PARENTERAL ADMINISTRATION MARKET, BY REGION
7.3.2.1 NORTH AMERICA PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.3.2.2 EUROPE PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.3.2.3 ASIA-PACIFIC PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.3.2.4 REST OF THE WORLD PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.4 OTHER ROUTES
7.4.1 OTHER ROUTES MARKET, BY REGION
7.4.1.1 NORTH AMERICA OTHER ROUTES MARKET, BY COUNTRY
7.4.1.2 EUROPE OTHER ROUTES MARKET, BY COUNTRY
7.4.1.3 ASIA-PACIFIC OTHER ROUTES MARKET, BY COUNTRY
7.4.1.4 REST OF THE WORLD OTHER ROUTES MARKET, BY COUNTRY
8 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY PATIENT TYPE
8.1 OVERVIEW
8.2 ADULT PATIENTS
8.2.1 GLOBAL ADULT PATIENTS MARKET, BY PATIENT TYPE
8.2.1.1 YOUNG ADULTS (18–40 YEARS) MARKET, BY REGION
8.2.1.1.1 NORTH AMERICA YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.1.2 EUROPE YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.1.3 ASIA-PACIFIC YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.1.4 REST OF THE WORLD YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.2 MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY REGION
8.2.1.2.1 NORTH AMERICA MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.2.2 EUROPE MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.2.3 ASIA-PACIFIC MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.2.4 REST OF THE WORLD MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.3 SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY REGION
8.2.1.3.1 NORTH AMERICA SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.1.3.2 EUROPE SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.1.3.3 ASIA-PACIFIC SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.1.3.4 REST OF THE WORLD SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.2 ADULT PATIENTS MARKET, BY REGION
8.2.2.1 NORTH AMERICA ADULT PATIENTS MARKET, BY COUNTRY
8.2.2.2 EUROPE ADULT PATIENTS MARKET, BY COUNTRY
8.2.2.3 ASIA-PACIFIC ADULT PATIENTS MARKET, BY COUNTRY
8.2.2.4 REST OF THE WORLD ADULT PATIENTS MARKET, BY COUNTRY
8.3 PEDIATRIC PATIENTS
8.3.1 GLOBAL PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
8.3.1.1 ADOLESCENTS (12–17 YEARS) MARKET, BY REGION
8.3.1.1.1 NORTH AMERICA ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.1.2 EUROPE ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.1.3 ASIA-PACIFIC ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.1.4 REST OF THE WORLD ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.2 CHILDREN (2–11 YEARS) MARKET, BY REGION
8.3.1.2.1 NORTH AMERICA CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.2.2 EUROPE CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.2.3 ASIA-PACIFIC CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.2.4 REST OF THE WORLD CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.3 INFANTS (1 MONTH–1 YEAR) MARKET, BY REGION
8.3.1.3.1 NORTH AMERICA INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.3.2 EUROPE INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.3.3 ASIA-PACIFIC INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.3.4 REST OF THE WORLD INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.4 NEONATES (LESS THAN 1 MONTH) MARKET, BY REGION
8.3.1.4.1 NORTH AMERICA NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.1.4.2 EUROPE NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.1.4.3 ASIA-PACIFIC NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.1.4.4 REST OF THE WORLD NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.2 PEDIATRIC PATIENTS MARKET, BY REGION
8.3.2.1 NORTH AMERICA PEDIATRIC PATIENTS MARKET, BY COUNTRY
8.3.2.2 EUROPE PEDIATRIC PATIENTS MARKET, BY COUNTRY
8.3.2.3 ASIA-PACIFIC PEDIATRIC PATIENTS MARKET, BY COUNTRY
8.3.2.4 REST OF THE WORLD PEDIATRIC PATIENTS MARKET, BY COUNTRY
9 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY APPLICATION/INDICATION (DISEASE LEVEL)
9.1 OVERVIEW
9.2 GYNECOLOGICAL INFECTIONS
9.2.1 GLOBAL GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.2.1.1 PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY REGION
9.2.1.1.1 NORTH AMERICA PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.1.2 EUROPE PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.1.3 ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.1.4 REST OF THE WORLD PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.2 BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY REGION
9.2.1.2.1 NORTH AMERICA BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.2.2 EUROPE BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.2.3 ASIA-PACIFIC BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.2.4 REST OF THE WORLD BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.3 OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY REGION
9.2.1.3.1 NORTH AMERICA OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.1.3.2 EUROPE OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.1.3.3 ASIA-PACIFIC OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.1.3.4 REST OF THE WORLD OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.2 GYNECOLOGICAL INFECTIONS MARKET, BY REGION
9.2.2.1 NORTH AMERICA GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.2.2.2 EUROPE GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.2.2.3 ASIA-PACIFIC GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.2.2.4 REST OF THE WORLD GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.3 INTRABDOMINAL INFECTIONS
9.3.1 GLOBAL INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.3.1.1 UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY REGION
9.3.1.1.1 NORTH AMERICA UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.1.1.2 EUROPE UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.1.1.3 ASIA-PACIFIC UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.1.1.4 REST OF THE WORLD UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.2 INTRABDOMINAL INFECTIONS MARKET, BY REGION
9.3.2.1 NORTH AMERICA INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.3.2.2 EUROPE INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.3.2.3 ASIA-PACIFIC INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.3.2.4 REST OF THE WORLD INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.4 INTRAOPERATIVE PROPHYLAXIS
9.4.1 INTRAOPERATIVE PROPHYLAXIS MARKET, BY REGION
9.4.1.1 NORTH AMERICA INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.4.1.2 EUROPE INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.4.1.3 ASIA-PACIFIC INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.4.1.4 REST OF THE WORLD INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.5 RESPIRATORY INFECTIONS
9.5.1 GLOBAL RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.5.1.1 COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY REGION
9.5.1.1.1 NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.1.2 EUROPE COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.1.3 ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.1.4 REST OF THE WORLD COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.2 NOSOCOMIAL PNEUMONIA MARKET, BY REGION
9.5.1.2.1 NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.1.2.2 EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.1.2.3 ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.1.2.4 REST OF THE WORLD NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.2 RESPIRATORY INFECTIONS MARKET, BY REGION
9.5.2.1 NORTH AMERICA RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.5.2.2 EUROPE RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.5.2.3 ASIA-PACIFIC RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.5.2.4 REST OF THE WORLD RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.6 SKIN AND SOFT TISSUE INFECTIONS (SSTI)
9.6.1 GLOBAL SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.6.1.1 CELLULITIS MARKET, BY REGION
9.6.1.1.1 NORTH AMERICA CELLULITIS MARKET, BY COUNTRY
9.6.1.1.2 EUROPE CELLULITIS MARKET, BY COUNTRY
9.6.1.1.3 ASIA-PACIFIC CELLULITIS MARKET, BY COUNTRY
9.6.1.1.4 REST OF THE WORLD CELLULITIS MARKET, BY COUNTRY
9.6.1.2 ERYSIPELAS MARKET, BY REGION
9.6.1.2.1 NORTH AMERICA ERYSIPELAS MARKET, BY COUNTRY
9.6.1.2.2 EUROPE ERYSIPELAS MARKET, BY COUNTRY
9.6.1.2.3 ASIA-PACIFIC ERYSIPELAS MARKET, BY COUNTRY
9.6.1.2.4 REST OF THE WORLD ERYSIPELAS MARKET, BY COUNTRY
9.6.1.3 IMPETIGO MARKET, BY REGION
9.6.1.3.1 NORTH AMERICA IMPETIGO MARKET, BY COUNTRY
9.6.1.3.2 EUROPE IMPETIGO MARKET, BY COUNTRY
9.6.1.3.3 ASIA-PACIFIC IMPETIGO MARKET, BY COUNTRY
9.6.1.3.4 REST OF THE WORLD IMPETIGO MARKET, BY COUNTRY
9.6.1.4 OTHER SSTIS MARKET, BY REGION
9.6.1.4.1 NORTH AMERICA OTHER SSTIS MARKET, BY COUNTRY
9.6.1.4.2 EUROPE OTHER SSTIS MARKET, BY COUNTRY
9.6.1.4.3 ASIA-PACIFIC OTHER SSTIS MARKET, BY COUNTRY
9.6.1.4.4 REST OF THE WORLD OTHER SSTIS MARKET, BY COUNTRY
9.6.2 SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY REGION
9.6.2.1 NORTH AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.6.2.2 EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.6.2.3 ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.6.2.4 REST OF THE WORLD SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.7 URINARY TRACT INFECTIONS (UTI)
9.7.1 GLOBAL URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.7.1.1 ACUTE UNCOMPLICATED UTI MARKET, BY REGION
9.7.1.1.1 NORTH AMERICA ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.1.2 EUROPE ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.1.3 ASIA-PACIFIC ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.1.4 REST OF THE WORLD ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.2 CHRONIC/RECURRENT UTI MARKET, BY REGION
9.7.1.2.1 NORTH AMERICA CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.2.2 EUROPE CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.2.3 ASIA-PACIFIC CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.2.4 REST OF THE WORLD CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.3 COMPLICATED UTI MARKET, BY REGION
9.7.1.3.1 NORTH AMERICA COMPLICATED UTI MARKET, BY COUNTRY
9.7.1.3.2 EUROPE COMPLICATED UTI MARKET, BY COUNTRY
9.7.1.3.3 ASIA-PACIFIC COMPLICATED UTI MARKET, BY COUNTRY
9.7.1.3.4 REST OF THE WORLD COMPLICATED UTI MARKET, BY COUNTRY
9.7.2 URINARY TRACT INFECTIONS (UTI) MARKET, BY REGION
9.7.2.1 NORTH AMERICA URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.7.2.2 EUROPE URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.7.2.3 ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.7.2.4 REST OF THE WORLD URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.8 BLOODSTREAM INFECTIONS (BSI)
9.8.1 BLOODSTREAM INFECTIONS (BSI) MARKET, BY REGION
9.8.1.1 NORTH AMERICA BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.8.1.2 EUROPE BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.8.1.3 ASIA-PACIFIC BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.8.1.4 REST OF THE WORLD BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.9 OTHER INFECTIONS
9.9.1 GLOBAL OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.9.1.1 MENINGITIS MARKET, BY REGION
9.9.1.1.1 NORTH AMERICA MENINGITIS MARKET, BY COUNTRY
9.9.1.1.2 EUROPE MENINGITIS MARKET, BY COUNTRY
9.9.1.1.3 ASIA-PACIFIC MENINGITIS MARKET, BY COUNTRY
9.9.1.1.4 REST OF THE WORLD MENINGITIS MARKET, BY COUNTRY
9.9.1.2 OSTEOMYELITIS MARKET, BY REGION
9.9.1.2.1 NORTH AMERICA OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.2.2 EUROPE OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.2.3 ASIA-PACIFIC OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.2.4 REST OF THE WORLD OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.3 ENDOCARDITIS MARKET, BY REGION
9.9.1.3.1 NORTH AMERICA ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.3.2 EUROPE ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.3.3 ASIA-PACIFIC ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.3.4 REST OF THE WORLD ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.4 OTHER RARE/OFF-LABEL USES MARKET, BY REGION
9.9.1.4.1 NORTH AMERICA OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.1.4.2 EUROPE OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.1.4.3 ASIA-PACIFIC OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.1.4.4 REST OF THE WORLD OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.2 OTHER INFECTIONS MARKET, BY REGION
9.9.2.1 NORTH AMERICA OTHER INFECTIONS MARKET, BY COUNTRY
9.9.2.2 EUROPE OTHER INFECTIONS MARKET, BY COUNTRY
9.9.2.3 ASIA-PACIFIC OTHER INFECTIONS MARKET, BY COUNTRY
9.9.2.4 REST OF THE WORLD OTHER INFECTIONS MARKET, BY COUNTRY
10 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY END USER (HEALTHCARE SETTING)
10.1 OVERVIEW
10.2 ACADEMIC INSTITUTIONS
10.2.1 ACADEMIC INSTITUTIONS MARKET, BY REGION
10.2.1.1 NORTH AMERICA ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.2.1.2 EUROPE ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.2.1.3 ASIA-PACIFIC ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.2.1.4 REST OF THE WORLD ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.3 CLINICS
10.3.1 CLINICS MARKET, BY REGION
10.3.1.1 NORTH AMERICA CLINICS MARKET, BY COUNTRY
10.3.1.2 EUROPE CLINICS MARKET, BY COUNTRY
10.3.1.3 ASIA-PACIFIC CLINICS MARKET, BY COUNTRY
10.3.1.4 REST OF THE WORLD CLINICS MARKET, BY COUNTRY
10.4 HOSPITALS
10.4.1 HOSPITALS MARKET, BY REGION
10.4.1.1 NORTH AMERICA HOSPITALS MARKET, BY COUNTRY
10.4.1.2 EUROPE HOSPITALS MARKET, BY COUNTRY
10.4.1.3 ASIA-PACIFIC HOSPITALS MARKET, BY COUNTRY
10.4.1.4 REST OF THE WORLD HOSPITALS MARKET, BY COUNTRY
10.5 RESEARCH LABORATORIES
10.5.1 RESEARCH LABORATORIES MARKET, BY REGION
10.5.1.1 NORTH AMERICA RESEARCH LABORATORIES MARKET, BY COUNTRY
10.5.1.2 EUROPE RESEARCH LABORATORIES MARKET, BY COUNTRY
10.5.1.3 ASIA-PACIFIC RESEARCH LABORATORIES MARKET, BY COUNTRY
10.5.1.4 REST OF THE WORLD RESEARCH LABORATORIES MARKET, BY COUNTRY
11 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.1.1 NORTH AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.1.2 NORTH AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.2 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.2.1 NORTH AMERICA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.2.2 NORTH AMERICA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.3 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.3.1 NORTH AMERICA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.3.2 NORTH AMERICA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.4 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.1 NORTH AMERICA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.2 NORTH AMERICA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.3 NORTH AMERICA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.4 NORTH AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.5 NORTH AMERICA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.6 NORTH AMERICA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.5 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.2.6 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.2.6.1 UNITED STATES
11.2.6.1.1 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.6.1.1.1 UNITED STATES INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.6.1.1.2 UNITED STATES BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.6.1.2 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.1.2.1 UNITED STATES ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.1.2.2 UNITED STATES PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.1.3 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.6.1.3.1 UNITED STATES ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.6.1.3.2 UNITED STATES PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.6.1.4 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.1 UNITED STATES GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.2 UNITED STATES INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.3 UNITED STATES RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.4 UNITED STATES SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.5 UNITED STATES URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.6 UNITED STATES OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.5 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.2.6.2 CANADA
11.2.6.2.1 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.6.2.1.1 CANADA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.6.2.1.2 CANADA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.6.2.2 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.2.2.1 CANADA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.2.2.2 CANADA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.2.3 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.6.2.3.1 CANADA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.6.2.3.2 CANADA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.6.2.4 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.1 CANADA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.2 CANADA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.3 CANADA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.4 CANADA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.5 CANADA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.6 CANADA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.5 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.2.6.3 MEXICO
11.2.6.3.1 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.6.3.1.1 MEXICO INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.6.3.1.2 MEXICO BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.6.3.2 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.3.2.1 MEXICO ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.3.2.2 MEXICO PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.3.3 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.6.3.3.1 MEXICO ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.6.3.3.2 MEXICO PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.6.3.4 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.1 MEXICO GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.2 MEXICO INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.3 MEXICO RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.4 MEXICO SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.5 MEXICO URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.6 MEXICO OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.5 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3 EUROPE
11.3.1 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.1.1 EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.1.2 EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.2 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.2.1 EUROPE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.2.2 EUROPE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.3 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.3.1 EUROPE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.3.2 EUROPE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.4 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.1 EUROPE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.2 EUROPE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.3 EUROPE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.4 EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.5 EUROPE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.6 EUROPE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.5 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.3.6.1 GERMANY
11.3.6.1.1 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.1.1.1 GERMANY INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.1.1.2 GERMANY BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.1.2 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.1.2.1 GERMANY ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.1.2.2 GERMANY PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.1.3 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.1.3.1 GERMANY ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.1.3.2 GERMANY PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.1.4 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.1 GERMANY GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.2 GERMANY INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.3 GERMANY RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.4 GERMANY SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.5 GERMANY URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.6 GERMANY OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.5 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.2 FRANCE
11.3.6.2.1 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.2.1.1 FRANCE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.2.1.2 FRANCE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.2.2 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.2.2.1 FRANCE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.2.2.2 FRANCE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.2.3 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.2.3.1 FRANCE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.2.3.2 FRANCE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.2.4 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.1 FRANCE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.2 FRANCE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.3 FRANCE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.4 FRANCE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.5 FRANCE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.6 FRANCE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.5 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.3 ITALY
11.3.6.3.1 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.3.1.1 ITALY INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.3.1.2 ITALY BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.3.2 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.3.2.1 ITALY ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.3.2.2 ITALY PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.3.3 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.3.3.1 ITALY ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.3.3.2 ITALY PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.3.4 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.1 ITALY GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.2 ITALY INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.3 ITALY RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.4 ITALY SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.5 ITALY URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.6 ITALY OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.5 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.4 SPAIN
11.3.6.4.1 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.4.1.1 SPAIN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.4.1.2 SPAIN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.4.2 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.4.2.1 SPAIN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.4.2.2 SPAIN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.4.3 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.4.3.1 SPAIN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.4.3.2 SPAIN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.4.4 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.1 SPAIN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.2 SPAIN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.3 SPAIN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.4 SPAIN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.5 SPAIN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.6 SPAIN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.5 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.5 UNITED KINGDOM
11.3.6.5.1 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.5.1.1 UNITED KINGDOM INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.5.1.2 UNITED KINGDOM BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.5.2 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.5.2.1 UNITED KINGDOM ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.5.2.2 UNITED KINGDOM PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.5.3 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.5.3.1 UNITED KINGDOM ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.5.3.2 UNITED KINGDOM PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.5.4 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.1 UNITED KINGDOM GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.2 UNITED KINGDOM INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.3 UNITED KINGDOM RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.4 UNITED KINGDOM SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.5 UNITED KINGDOM URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.6 UNITED KINGDOM OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.5 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.6 RUSSIA
11.3.6.6.1 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.6.1.1 RUSSIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.6.1.2 RUSSIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.6.2 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.6.2.1 RUSSIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.6.2.2 RUSSIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.6.3 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.6.3.1 RUSSIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.6.3.2 RUSSIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.6.4 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.1 RUSSIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.2 RUSSIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.3 RUSSIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.4 RUSSIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.5 RUSSIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.6 RUSSIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.5 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.7 SWEDEN
11.3.6.7.1 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.7.1.1 SWEDEN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.7.1.2 SWEDEN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.7.2 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.7.2.1 SWEDEN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.7.2.2 SWEDEN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.7.3 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.7.3.1 SWEDEN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.7.3.2 SWEDEN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.7.4 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.1 SWEDEN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.2 SWEDEN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.3 SWEDEN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.4 SWEDEN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.5 SWEDEN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.6 SWEDEN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.5 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.8 NORWAY
11.3.6.8.1 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.8.1.1 NORWAY INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.8.1.2 NORWAY BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.8.2 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.8.2.1 NORWAY ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.8.2.2 NORWAY PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.8.3 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.8.3.1 NORWAY ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.8.3.2 NORWAY PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.8.4 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.1 NORWAY GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.2 NORWAY INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.3 NORWAY RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.4 NORWAY SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.5 NORWAY URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.6 NORWAY OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.5 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.9 DENMARK
11.3.6.9.1 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.9.1.1 DENMARK INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.9.1.2 DENMARK BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.9.2 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.9.2.1 DENMARK ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.9.2.2 DENMARK PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.9.3 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.9.3.1 DENMARK ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.9.3.2 DENMARK PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.9.4 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.1 DENMARK GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.2 DENMARK INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.3 DENMARK RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.4 DENMARK SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.5 DENMARK URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.6 DENMARK OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.5 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.10 NETHERLANDS
11.3.6.10.1 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.10.1.1 NETHERLANDS INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.10.1.2 NETHERLANDS BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.10.2 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.10.2.1 NETHERLANDS ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.10.2.2 NETHERLANDS PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.10.3 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.10.3.1 NETHERLANDS ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.10.3.2 NETHERLANDS PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.10.4 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.1 NETHERLANDS GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.2 NETHERLANDS INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.3 NETHERLANDS RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.4 NETHERLANDS SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.5 NETHERLANDS URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.6 NETHERLANDS OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.5 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.11 FINLAND
11.3.6.11.1 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.11.1.1 FINLAND INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.11.1.2 FINLAND BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.11.2 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.11.2.1 FINLAND ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.11.2.2 FINLAND PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.11.3 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.11.3.1 FINLAND ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.11.3.2 FINLAND PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.11.4 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.1 FINLAND GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.2 FINLAND INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.3 FINLAND RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.4 FINLAND SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.5 FINLAND URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.6 FINLAND OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.5 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.12 REST OF EUROPE
11.3.6.12.1 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.12.1.1 REST OF EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.12.1.2 REST OF EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.12.2 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.12.2.1 REST OF EUROPE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.12.2.2 REST OF EUROPE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.12.3 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.12.3.1 REST OF EUROPE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.12.3.2 REST OF EUROPE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.12.4 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.1 REST OF EUROPE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.2 REST OF EUROPE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.3 REST OF EUROPE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.4 REST OF EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.5 REST OF EUROPE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.6 REST OF EUROPE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.5 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4 ASIA-PACIFIC
11.4.1 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.1.1 ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.1.2 ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.2 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.2.1 ASIA-PACIFIC ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.2.2 ASIA-PACIFIC PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.3 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.3.1 ASIA-PACIFIC ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.3.2 ASIA-PACIFIC PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.4 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.1 ASIA-PACIFIC GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.2 ASIA-PACIFIC INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.3 ASIA-PACIFIC RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.4 ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.5 ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.6 ASIA-PACIFIC OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.5 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.4.6.1 AUSTRALIA
11.4.6.1.1 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.1.1.1 AUSTRALIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.1.1.2 AUSTRALIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.1.2 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.1.2.1 AUSTRALIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.1.2.2 AUSTRALIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.1.3 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.1.3.1 AUSTRALIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.1.3.2 AUSTRALIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.1.4 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.1 AUSTRALIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.2 AUSTRALIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.3 AUSTRALIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.4 AUSTRALIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.5 AUSTRALIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.6 AUSTRALIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.5 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.2 CHINA
11.4.6.2.1 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.2.1.1 CHINA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.2.1.2 CHINA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.2.2 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.2.2.1 CHINA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.2.2.2 CHINA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.2.3 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.2.3.1 CHINA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.2.3.2 CHINA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.2.4 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.1 CHINA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.2 CHINA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.3 CHINA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.4 CHINA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.5 CHINA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.6 CHINA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.5 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.3 INDIA
11.4.6.3.1 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.3.1.1 INDIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.3.1.2 INDIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.3.2 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.3.2.1 INDIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.3.2.2 INDIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.3.3 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.3.3.1 INDIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.3.3.2 INDIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.3.4 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.1 INDIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.2 INDIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.3 INDIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.4 INDIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.5 INDIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.6 INDIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.5 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.4 JAPAN
11.4.6.4.1 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.4.1.1 JAPAN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.4.1.2 JAPAN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.4.2 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.4.2.1 JAPAN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.4.2.2 JAPAN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.4.3 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.4.3.1 JAPAN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.4.3.2 JAPAN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.4.4 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.1 JAPAN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.2 JAPAN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.3 JAPAN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.4 JAPAN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.5 JAPAN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.6 JAPAN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.5 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.5 SOUTH KOREA
11.4.6.5.1 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.5.1.1 SOUTH KOREA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.5.1.2 SOUTH KOREA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.5.2 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.5.2.1 SOUTH KOREA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.5.2.2 SOUTH KOREA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.5.3 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.5.3.1 SOUTH KOREA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.5.3.2 SOUTH KOREA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.5.4 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.1 SOUTH KOREA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.2 SOUTH KOREA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.3 SOUTH KOREA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.4 SOUTH KOREA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.5 SOUTH KOREA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.6 SOUTH KOREA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.5 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.6 INDONESIA
11.4.6.6.1 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.6.1.1 INDONESIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.6.1.2 INDONESIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.6.2 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.6.2.1 INDONESIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.6.2.2 INDONESIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.6.3 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.6.3.1 INDONESIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.6.3.2 INDONESIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.6.4 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.1 INDONESIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.2 INDONESIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.3 INDONESIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.4 INDONESIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.5 INDONESIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.6 INDONESIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.5 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.7 SINGAPORE
11.4.6.7.1 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.7.1.1 SINGAPORE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.7.1.2 SINGAPORE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.7.2 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.7.2.1 SINGAPORE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.7.2.2 SINGAPORE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.7.3 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.7.3.1 SINGAPORE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.7.3.2 SINGAPORE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.7.4 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.1 SINGAPORE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.2 SINGAPORE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.3 SINGAPORE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.4 SINGAPORE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.5 SINGAPORE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.6 SINGAPORE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.5 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.8 TAIWAN
11.4.6.8.1 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.8.1.1 TAIWAN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.8.1.2 TAIWAN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.8.2 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.8.2.1 TAIWAN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.8.2.2 TAIWAN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.8.3 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.8.3.1 TAIWAN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.8.3.2 TAIWAN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.8.4 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.1 TAIWAN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.2 TAIWAN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.3 TAIWAN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.4 TAIWAN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.5 TAIWAN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.6 TAIWAN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.5 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.9 THAILAND
11.4.6.9.1 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.9.1.1 THAILAND INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.9.1.2 THAILAND BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.9.2 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.9.2.1 THAILAND ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.9.2.2 THAILAND PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.9.3 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.9.3.1 THAILAND ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.9.3.2 THAILAND PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.9.4 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.1 THAILAND GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.2 THAILAND INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.3 THAILAND RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.4 THAILAND SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.5 THAILAND URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.6 THAILAND OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.5 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.10 REST OF ASIA-PACIFIC
11.4.6.10.1 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.10.1.1 REST OF ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.10.1.2 REST OF ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.10.2 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.10.2.1 REST OF ASIA-PACIFIC ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.10.2.2 REST OF ASIA-PACIFIC PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.10.3 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.10.3.1 REST OF ASIA-PACIFIC ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.10.3.2 REST OF ASIA-PACIFIC PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.10.4 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.1 REST OF ASIA-PACIFIC GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.2 REST OF ASIA-PACIFIC INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.3 REST OF ASIA-PACIFIC RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.4 REST OF ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.5 REST OF ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.6 REST OF ASIA-PACIFIC OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.5 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5 REST OF THE WORLD
11.5.1 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.1.1 REST OF THE WORLD INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.1.2 REST OF THE WORLD BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.2 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.2.1 REST OF THE WORLD ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.2.2 REST OF THE WORLD PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.3 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.3.1 REST OF THE WORLD ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.3.2 REST OF THE WORLD PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.4 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.1 REST OF THE WORLD GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.2 REST OF THE WORLD INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.3 REST OF THE WORLD RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.4 REST OF THE WORLD SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.5 REST OF THE WORLD URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.6 REST OF THE WORLD OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.5 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5.6 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.5.6.1 LATIN AMERICA
11.5.6.1.1 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.6.1.1.1 LATIN AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.6.1.1.2 LATIN AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.6.1.2 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.1.2.1 LATIN AMERICA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.1.2.2 LATIN AMERICA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.1.3 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.6.1.3.1 LATIN AMERICA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.6.1.3.2 LATIN AMERICA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.6.1.4 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.1 LATIN AMERICA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.2 LATIN AMERICA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.3 LATIN AMERICA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.4 LATIN AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.5 LATIN AMERICA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.6 LATIN AMERICA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.5 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5.6.2 MIDDLE EAST
11.5.6.2.1 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.6.2.1.1 MIDDLE EAST INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.6.2.1.2 MIDDLE EAST BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.6.2.2 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.2.2.1 MIDDLE EAST ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.2.2.2 MIDDLE EAST PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.2.3 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.6.2.3.1 MIDDLE EAST ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.6.2.3.2 MIDDLE EAST PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.6.2.4 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.1 MIDDLE EAST GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.2 MIDDLE EAST INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.3 MIDDLE EAST RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.4 MIDDLE EAST SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.5 MIDDLE EAST URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.6 MIDDLE EAST OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.5 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5.6.3 AFRICA
11.5.6.3.1 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.6.3.1.1 AFRICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.6.3.1.2 AFRICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.6.3.2 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.3.2.1 AFRICA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.3.2.2 AFRICA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.3.3 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.6.3.3.1 AFRICA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.6.3.3.2 AFRICA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.6.3.4 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.1 AFRICA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.2 AFRICA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.3 AFRICA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.4 AFRICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.5 AFRICA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.6 AFRICA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.5 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
12 COMPANY PROFILES
12.1 AUROBINDO PHARMA
12.1.1 COMPANY OVERVIEW
12.1.2 COMPANY SNAPSHOT
12.1.3 OPERATING BUSINESS SEGMENTS
12.1.4 PRODUCT PORTFOLIO
12.1.5 BUSINESS PERFORMANCE
12.1.6 BUSINESS SEGMENTS
12.1.7 GEOGRAPHIC SEGMENTS
12.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.1.9 PRIMARY MARKET COMPETITORS
12.2 CIPLA INC.
12.2.1 COMPANY OVERVIEW
12.2.2 COMPANY SNAPSHOT
12.2.3 OPERATING BUSINESS SEGMENTS
12.2.4 PRODUCT PORTFOLIO
12.2.5 BUSINESS PERFORMANCE
12.2.6 BUSINESS SEGMENTS
12.2.7 GEOGRAPHIC SEGMENTS
12.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.2.9 PRIMARY MARKET COMPETITORS
12.3 DR. REDDY’S LABORATORIES LTD.
12.3.1 COMPANY OVERVIEW
12.3.2 COMPANY SNAPSHOT
12.3.3 OPERATING BUSINESS SEGMENTS
12.3.4 PRODUCT PORTFOLIO
12.3.5 BUSINESS PERFORMANCE
12.3.6 BUSINESS SEGMENTS
12.3.7 GEOGRAPHIC SEGMENTS
12.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.3.9 PRIMARY MARKET COMPETITORS
12.4 GLAXOSMITHKLINE PLC
12.4.1 COMPANY OVERVIEW
12.4.2 COMPANY SNAPSHOT
12.4.3 OPERATING BUSINESS SEGMENTS
12.4.4 PRODUCT PORTFOLIO
12.4.5 BUSINESS PERFORMANCE
12.4.6 BUSINESS SEGMENTS
12.4.7 GEOGRAPHIC SEGMENTS
12.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.4.9 PRIMARY MARKET COMPETITORS
12.5 HIKMA PHARMACEUTICALS PLC
12.5.1 COMPANY OVERVIEW
12.5.2 COMPANY SNAPSHOT
12.5.3 OPERATING BUSINESS SEGMENTS
12.5.4 PRODUCT PORTFOLIO
12.5.5 BUSINESS PERFORMANCE
12.5.6 BUSINESS SEGMENTS
12.5.7 GEOGRAPHIC SEGMENTS
12.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.5.9 PRIMARY MARKET COMPETITORS
12.6 LUPIN LTD.
12.6.1 COMPANY OVERVIEW
12.6.2 COMPANY SNAPSHOT
12.6.3 OPERATING BUSINESS SEGMENTS
12.6.4 PRODUCT PORTFOLIO
12.6.5 BUSINESS PERFORMANCE
12.6.6 BUSINESS SEGMENTS
12.6.7 GEOGRAPHIC SEGMENTS
12.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.6.9 PRIMARY MARKET COMPETITORS
12.7 MEIJI HOLDINGS CO. LTD.
12.7.1 COMPANY OVERVIEW
12.7.2 COMPANY SNAPSHOT
12.7.3 OPERATING BUSINESS SEGMENTS
12.7.4 PRODUCT PORTFOLIO
12.7.5 BUSINESS PERFORMANCE
12.7.6 BUSINESS SEGMENTS
12.7.7 GEOGRAPHIC SEGMENTS
12.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.7.9 PRIMARY MARKET COMPETITORS
12.8 MERCK & CO. INC.
12.8.1 COMPANY OVERVIEW
12.8.2 COMPANY SNAPSHOT
12.8.3 OPERATING BUSINESS SEGMENTS
12.8.4 PRODUCT PORTFOLIO
12.8.5 BUSINESS PERFORMANCE
12.8.6 BUSINESS SEGMENTS
12.8.7 GEOGRAPHIC SEGMENTS
12.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.8.9 PRIMARY MARKET COMPETITORS
12.9 PFIZER INC.
12.9.1 COMPANY OVERVIEW
12.9.2 COMPANY SNAPSHOT
12.9.3 OPERATING BUSINESS SEGMENTS
12.9.4 PRODUCT PORTFOLIO
12.9.5 BUSINESS PERFORMANCE
12.9.6 BUSINESS SEGMENTS
12.9.7 GEOGRAPHIC SEGMENTS
12.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.9.9 PRIMARY MARKET COMPETITORS
12.10 SANDOZ INTERNATIONAL GMBH (NOVARTIS)
12.10.1 COMPANY OVERVIEW
12.10.2 COMPANY SNAPSHOT
12.10.3 OPERATING BUSINESS SEGMENTS
12.10.4 PRODUCT PORTFOLIO
12.10.5 BUSINESS PERFORMANCE
12.10.6 BUSINESS SEGMENTS
12.10.7 GEOGRAPHIC SEGMENTS
12.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.10.9 PRIMARY MARKET COMPETITORS
12.11 SHIONOGI & CO., LTD.
12.11.1 COMPANY OVERVIEW
12.11.2 COMPANY SNAPSHOT
12.11.3 OPERATING BUSINESS SEGMENTS
12.11.4 PRODUCT PORTFOLIO
12.11.5 BUSINESS PERFORMANCE
12.11.6 BUSINESS SEGMENTS
12.11.7 GEOGRAPHIC SEGMENTS
12.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.11.9 PRIMARY MARKET COMPETITORS
12.12 SUN PHARMACEUTICAL INDUSTRIES LTD.
12.12.1 COMPANY OVERVIEW
12.12.2 COMPANY SNAPSHOT
12.12.3 OPERATING BUSINESS SEGMENTS
12.12.4 PRODUCT PORTFOLIO
12.12.5 BUSINESS PERFORMANCE
12.12.6 BUSINESS SEGMENTS
12.12.7 GEOGRAPHIC SEGMENTS
12.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.12.9 PRIMARY MARKET COMPETITORS
12.13 TAJ PHARMACEUTICALS LTD.
12.13.1 COMPANY OVERVIEW
12.13.2 COMPANY SNAPSHOT
12.13.3 OPERATING BUSINESS SEGMENTS
12.13.4 PRODUCT PORTFOLIO
12.13.5 BUSINESS PERFORMANCE
12.13.6 BUSINESS SEGMENTS
12.13.7 GEOGRAPHIC SEGMENTS
12.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.13.9 PRIMARY MARKET COMPETITORS
12.14 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.14.1 COMPANY OVERVIEW
12.14.2 COMPANY SNAPSHOT
12.14.3 OPERATING BUSINESS SEGMENTS
12.14.4 PRODUCT PORTFOLIO
12.14.5 BUSINESS PERFORMANCE
12.14.6 BUSINESS SEGMENTS
12.14.7 GEOGRAPHIC SEGMENTS
12.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.14.9 PRIMARY MARKET COMPETITORS
12.15 TORRENT PHARMACEUTICALS LTD.
12.15.1 COMPANY OVERVIEW
12.15.2 COMPANY SNAPSHOT
12.15.3 OPERATING BUSINESS SEGMENTS
12.15.4 PRODUCT PORTFOLIO
12.15.5 BUSINESS PERFORMANCE
12.15.6 BUSINESS SEGMENTS
12.15.7 GEOGRAPHIC SEGMENTS
12.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.15.9 PRIMARY MARKET COMPETITORS
12.16 VIATRIS (FORMERLY MYLAN N.V.)
12.16.1 COMPANY OVERVIEW
12.16.2 COMPANY SNAPSHOT
12.16.3 OPERATING BUSINESS SEGMENTS
12.16.4 PRODUCT PORTFOLIO
12.16.5 BUSINESS PERFORMANCE
12.16.6 BUSINESS SEGMENTS
12.16.7 GEOGRAPHIC SEGMENTS
12.16.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.16.9 PRIMARY MARKET COMPETITORS
12.17 ZEELAB LABORATORIES LTD.
12.17.1 COMPANY OVERVIEW
12.17.2 COMPANY SNAPSHOT
12.17.3 OPERATING BUSINESS SEGMENTS
12.17.4 PRODUCT PORTFOLIO
12.17.5 BUSINESS PERFORMANCE
12.17.6 BUSINESS SEGMENTS
12.17.7 GEOGRAPHIC SEGMENTS
12.17.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.17.9 PRIMARY MARKET COMPETITORS
12.18 ZENTIVA GROUP B.V.
12.18.1 COMPANY OVERVIEW
12.18.2 COMPANY SNAPSHOT
12.18.3 OPERATING BUSINESS SEGMENTS
12.18.4 PRODUCT PORTFOLIO
12.18.5 BUSINESS PERFORMANCE
12.18.6 BUSINESS SEGMENTS
12.18.7 GEOGRAPHIC SEGMENTS
12.18.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.18.9 PRIMARY MARKET COMPETITORS
12.19 ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE)
12.19.1 COMPANY OVERVIEW
12.19.2 COMPANY SNAPSHOT
12.19.3 OPERATING BUSINESS SEGMENTS
12.19.4 PRODUCT PORTFOLIO
12.19.5 BUSINESS PERFORMANCE
12.19.6 BUSINESS SEGMENTS
12.19.7 GEOGRAPHIC SEGMENTS
12.19.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.19.9 PRIMARY MARKET COMPETITORS
1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2 BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET – EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT, 2024 - 2030, BILLION USD
3 PORTER’S FIVE FORCE MODEL ANALYSIS
3.1 BARGAINING POWER OF SUPPLIERS
3.2 BARGAINING POWER OF BUYERS
3.3 DEGREE OF COMPETITION
3.4 THREAT OF SUBSTITUTE
3.5 THREAT OF NEW ENTRANTS
4 MARKET SHARE ANALYSIS
4.1 MARKET SHARE ANALYSIS OF TOP PROVIDERS, 2024
5 MARKET DYNAMICS
5.1 GROWTH DRIVERS
5.1.1 DRIVER 1
5.1.2 DRIVER 2
5.1.3 DRIVER 3
5.1.4 DRIVER 4
5.2 CHALLENGES
5.2.1 CHALLENGE 1
5.2.2 CHALLENGE 2
5.2.3 CHALLENGE 3
5.2.4 CHALLENGE 4
5.3 OPPORTUNITIES
5.3.1 OPPORTUNITY 1
5.3.2 OPPORTUNITY 2
6 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY TYPE
6.1 OVERVIEW
6.2 INDIVIDUAL BETA-LACTAM ANTIBIOTICS
6.2.1 GLOBAL INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
6.2.1.1 PENICILLINS MARKET, BY REGION
6.2.1.1.1 NATURAL PENICILLINS
6.2.1.1.2 AMINOPENICILLINS
6.2.1.1.3 EXTENDED-SPECTRUM PENICILLINS
6.2.1.1.1.1 NORTH AMERICA PENICILLINS MARKET, BY COUNTRY
6.2.1.1.1.2 EUROPE PENICILLINS MARKET, BY COUNTRY
6.2.1.1.1.3 ASIA-PACIFIC PENICILLINS MARKET, BY COUNTRY
6.2.1.1.1.4 REST OF THE WORLD PENICILLINS MARKET, BY COUNTRY
6.2.1.2 CEPHALOSPORINS MARKET, BY REGION
6.2.1.2.1 FIRST-GENERATION
6.2.1.2.2 SECOND-GENERATION
6.2.1.2.3 THIRD-GENERATION
6.2.1.2.4 FOURTH-GENERATION
6.2.1.2.5 FIFTH-GENERATION
6.2.1.2.1.1 NORTH AMERICA CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.2.1.2 EUROPE CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.2.1.3 ASIA-PACIFIC CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.2.1.4 REST OF THE WORLD CEPHALOSPORINS MARKET, BY COUNTRY
6.2.1.3 CARBAPENEMS MARKET, BY REGION
6.2.1.3.1 DORIPENEM
6.2.1.3.2 ERTAPENEM
6.2.1.3.3 IMIPENEM
6.2.1.3.4 MEROPENEM
6.2.1.3.1.1 NORTH AMERICA CARBAPENEMS MARKET, BY COUNTRY
6.2.1.3.1.2 EUROPE CARBAPENEMS MARKET, BY COUNTRY
6.2.1.3.1.3 ASIA-PACIFIC CARBAPENEMS MARKET, BY COUNTRY
6.2.1.3.1.4 REST OF THE WORLD CARBAPENEMS MARKET, BY COUNTRY
6.2.1.4 MONOBACTAMS MARKET, BY REGION
6.2.1.4.1 NORTH AMERICA MONOBACTAMS MARKET, BY COUNTRY
6.2.1.4.2 EUROPE MONOBACTAMS MARKET, BY COUNTRY
6.2.1.4.3 ASIA-PACIFIC MONOBACTAMS MARKET, BY COUNTRY
6.2.1.4.4 REST OF THE WORLD MONOBACTAMS MARKET, BY COUNTRY
6.2.2 INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY REGION
6.2.2.1 NORTH AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.2.2.2 EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.2.2.3 ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.2.2.4 REST OF THE WORLD INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY COUNTRY
6.3 BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS
6.3.1 GLOBAL BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
6.3.1.1 PENICILLIN COMBINATIONS MARKET, BY REGION
6.3.1.1.1 AMOXICILLIN-CLAVULANATE
6.3.1.1.2 AMPICILLIN-SULBACTAM
6.3.1.1.3 PIPERACILLIN-TAZOBACTAM
6.3.1.1.4 TICARCILLIN-CLAVULANATE
6.3.1.1.1.1 NORTH AMERICA PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.1.1.2 EUROPE PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.1.1.3 ASIA-PACIFIC PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.1.1.4 REST OF THE WORLD PENICILLIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2 CEPHALOSPORIN COMBINATIONS MARKET, BY REGION
6.3.1.2.1 CEFTAZIDIME-AVIBACTAM
6.3.1.2.2 CEFEPIME-TAZOBACTAM
6.3.1.2.1 NORTH AMERICA CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2.2 EUROPE CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2.3 ASIA-PACIFIC CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.2.4 REST OF THE WORLD CEPHALOSPORIN COMBINATIONS MARKET, BY COUNTRY
6.3.1.3 CARBAPENEM COMBINATIONS MARKET, BY REGION
6.3.1.3.1 MEROPENEM-VABORBACTAM
6.3.1.3.2 IMIPENEM-RELEBACTAM
6.3.1.3.1.1 NORTH AMERICA CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.3.1.2 EUROPE CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.3.1.3 ASIA-PACIFIC CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.3.1.4 REST OF THE WORLD CARBAPENEM COMBINATIONS MARKET, BY COUNTRY
6.3.1.4 OTHERS MARKET, BY REGION
6.3.1.4.1 NORTH AMERICA OTHERS MARKET, BY COUNTRY
6.3.1.4.2 EUROPE OTHERS MARKET, BY COUNTRY
6.3.1.4.3 ASIA-PACIFIC OTHERS MARKET, BY COUNTRY
6.3.1.4.4 REST OF THE WORLD OTHERS MARKET, BY COUNTRY
6.3.2 BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY REGION
6.3.2.1 NORTH AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
6.3.2.2 EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
6.3.2.3 ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
6.3.2.4 REST OF THE WORLD BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY COUNTRY
7 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL ADMINISTRATION
7.2.1 GLOBAL ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
7.2.1.1 CAPSULES MARKET, BY REGION
7.2.1.1.1 NORTH AMERICA CAPSULES MARKET, BY COUNTRY
7.2.1.1.2 EUROPE CAPSULES MARKET, BY COUNTRY
7.2.1.1.3 ASIA-PACIFIC CAPSULES MARKET, BY COUNTRY
7.2.1.1.4 REST OF THE WORLD CAPSULES MARKET, BY COUNTRY
7.2.1.2 TABLETS MARKET, BY REGION
7.2.1.2.1 NORTH AMERICA TABLETS MARKET, BY COUNTRY
7.2.1.2.2 EUROPE TABLETS MARKET, BY COUNTRY
7.2.1.2.3 ASIA-PACIFIC TABLETS MARKET, BY COUNTRY
7.2.1.2.4 REST OF THE WORLD TABLETS MARKET, BY COUNTRY
7.2.2 ORAL ADMINISTRATION MARKET, BY REGION
7.2.2.1 NORTH AMERICA ORAL ADMINISTRATION MARKET, BY COUNTRY
7.2.2.2 EUROPE ORAL ADMINISTRATION MARKET, BY COUNTRY
7.2.2.3 ASIA-PACIFIC ORAL ADMINISTRATION MARKET, BY COUNTRY
7.2.2.4 REST OF THE WORLD ORAL ADMINISTRATION MARKET, BY COUNTRY
7.3 PARENTERAL ADMINISTRATION
7.3.1 GLOBAL PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
7.3.1.1 INTRAMUSCULAR INJECTION (IM) MARKET, BY REGION
7.3.1.1.1 NORTH AMERICA INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.1.2 EUROPE INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.1.3 ASIA-PACIFIC INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.1.4 REST OF THE WORLD INTRAMUSCULAR INJECTION (IM) MARKET, BY COUNTRY
7.3.1.2 INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY REGION
7.3.1.2.1 NORTH AMERICA INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.1.2.2 EUROPE INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.1.2.3 ASIA-PACIFIC INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.1.2.4 REST OF THE WORLD INTRAVENOUS INFUSION/INJECTION (IV) MARKET, BY COUNTRY
7.3.2 PARENTERAL ADMINISTRATION MARKET, BY REGION
7.3.2.1 NORTH AMERICA PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.3.2.2 EUROPE PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.3.2.3 ASIA-PACIFIC PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.3.2.4 REST OF THE WORLD PARENTERAL ADMINISTRATION MARKET, BY COUNTRY
7.4 OTHER ROUTES
7.4.1 OTHER ROUTES MARKET, BY REGION
7.4.1.1 NORTH AMERICA OTHER ROUTES MARKET, BY COUNTRY
7.4.1.2 EUROPE OTHER ROUTES MARKET, BY COUNTRY
7.4.1.3 ASIA-PACIFIC OTHER ROUTES MARKET, BY COUNTRY
7.4.1.4 REST OF THE WORLD OTHER ROUTES MARKET, BY COUNTRY
8 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY PATIENT TYPE
8.1 OVERVIEW
8.2 ADULT PATIENTS
8.2.1 GLOBAL ADULT PATIENTS MARKET, BY PATIENT TYPE
8.2.1.1 YOUNG ADULTS (18–40 YEARS) MARKET, BY REGION
8.2.1.1.1 NORTH AMERICA YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.1.2 EUROPE YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.1.3 ASIA-PACIFIC YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.1.4 REST OF THE WORLD YOUNG ADULTS (18–40 YEARS) MARKET, BY COUNTRY
8.2.1.2 MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY REGION
8.2.1.2.1 NORTH AMERICA MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.2.2 EUROPE MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.2.3 ASIA-PACIFIC MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.2.4 REST OF THE WORLD MIDDLE-AGED ADULTS (41–64 YEARS) MARKET, BY COUNTRY
8.2.1.3 SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY REGION
8.2.1.3.1 NORTH AMERICA SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.1.3.2 EUROPE SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.1.3.3 ASIA-PACIFIC SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.1.3.4 REST OF THE WORLD SENIOR ADULTS (MORE THAN 65 YEARS) MARKET, BY COUNTRY
8.2.2 ADULT PATIENTS MARKET, BY REGION
8.2.2.1 NORTH AMERICA ADULT PATIENTS MARKET, BY COUNTRY
8.2.2.2 EUROPE ADULT PATIENTS MARKET, BY COUNTRY
8.2.2.3 ASIA-PACIFIC ADULT PATIENTS MARKET, BY COUNTRY
8.2.2.4 REST OF THE WORLD ADULT PATIENTS MARKET, BY COUNTRY
8.3 PEDIATRIC PATIENTS
8.3.1 GLOBAL PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
8.3.1.1 ADOLESCENTS (12–17 YEARS) MARKET, BY REGION
8.3.1.1.1 NORTH AMERICA ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.1.2 EUROPE ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.1.3 ASIA-PACIFIC ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.1.4 REST OF THE WORLD ADOLESCENTS (12–17 YEARS) MARKET, BY COUNTRY
8.3.1.2 CHILDREN (2–11 YEARS) MARKET, BY REGION
8.3.1.2.1 NORTH AMERICA CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.2.2 EUROPE CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.2.3 ASIA-PACIFIC CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.2.4 REST OF THE WORLD CHILDREN (2–11 YEARS) MARKET, BY COUNTRY
8.3.1.3 INFANTS (1 MONTH–1 YEAR) MARKET, BY REGION
8.3.1.3.1 NORTH AMERICA INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.3.2 EUROPE INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.3.3 ASIA-PACIFIC INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.3.4 REST OF THE WORLD INFANTS (1 MONTH–1 YEAR) MARKET, BY COUNTRY
8.3.1.4 NEONATES (LESS THAN 1 MONTH) MARKET, BY REGION
8.3.1.4.1 NORTH AMERICA NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.1.4.2 EUROPE NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.1.4.3 ASIA-PACIFIC NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.1.4.4 REST OF THE WORLD NEONATES (LESS THAN 1 MONTH) MARKET, BY COUNTRY
8.3.2 PEDIATRIC PATIENTS MARKET, BY REGION
8.3.2.1 NORTH AMERICA PEDIATRIC PATIENTS MARKET, BY COUNTRY
8.3.2.2 EUROPE PEDIATRIC PATIENTS MARKET, BY COUNTRY
8.3.2.3 ASIA-PACIFIC PEDIATRIC PATIENTS MARKET, BY COUNTRY
8.3.2.4 REST OF THE WORLD PEDIATRIC PATIENTS MARKET, BY COUNTRY
9 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY APPLICATION/INDICATION (DISEASE LEVEL)
9.1 OVERVIEW
9.2 GYNECOLOGICAL INFECTIONS
9.2.1 GLOBAL GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.2.1.1 PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY REGION
9.2.1.1.1 NORTH AMERICA PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.1.2 EUROPE PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.1.3 ASIA-PACIFIC PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.1.4 REST OF THE WORLD PELVIC INFLAMMATORY DISEASE (PID) MARKET, BY COUNTRY
9.2.1.2 BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY REGION
9.2.1.2.1 NORTH AMERICA BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.2.2 EUROPE BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.2.3 ASIA-PACIFIC BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.2.4 REST OF THE WORLD BACTERIAL VAGINOSIS (IF TREATED WITH BETA-LACTAM) MARKET, BY COUNTRY
9.2.1.3 OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY REGION
9.2.1.3.1 NORTH AMERICA OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.1.3.2 EUROPE OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.1.3.3 ASIA-PACIFIC OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.1.3.4 REST OF THE WORLD OTHER FEMALE-REPRODUCTIVE-TRACT INFECTIONS MARKET, BY COUNTRY
9.2.2 GYNECOLOGICAL INFECTIONS MARKET, BY REGION
9.2.2.1 NORTH AMERICA GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.2.2.2 EUROPE GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.2.2.3 ASIA-PACIFIC GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.2.2.4 REST OF THE WORLD GYNECOLOGICAL INFECTIONS MARKET, BY COUNTRY
9.3 INTRABDOMINAL INFECTIONS
9.3.1 GLOBAL INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.3.1.1 UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY REGION
9.3.1.1.1 NORTH AMERICA UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.1.1.2 EUROPE UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.1.1.3 ASIA-PACIFIC UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.1.1.4 REST OF THE WORLD UNCOMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.3.2 INTRABDOMINAL INFECTIONS MARKET, BY REGION
9.3.2.1 NORTH AMERICA INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.3.2.2 EUROPE INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.3.2.3 ASIA-PACIFIC INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.3.2.4 REST OF THE WORLD INTRABDOMINAL INFECTIONS MARKET, BY COUNTRY
9.4 INTRAOPERATIVE PROPHYLAXIS
9.4.1 INTRAOPERATIVE PROPHYLAXIS MARKET, BY REGION
9.4.1.1 NORTH AMERICA INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.4.1.2 EUROPE INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.4.1.3 ASIA-PACIFIC INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.4.1.4 REST OF THE WORLD INTRAOPERATIVE PROPHYLAXIS MARKET, BY COUNTRY
9.5 RESPIRATORY INFECTIONS
9.5.1 GLOBAL RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.5.1.1 COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY REGION
9.5.1.1.1 NORTH AMERICA COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.1.2 EUROPE COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.1.3 ASIA-PACIFIC COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.1.4 REST OF THE WORLD COMPLICATED INTRA-ABDOMINAL INFECTION MARKET, BY COUNTRY
9.5.1.2 NOSOCOMIAL PNEUMONIA MARKET, BY REGION
9.5.1.2.1 NORTH AMERICA NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.1.2.2 EUROPE NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.1.2.3 ASIA-PACIFIC NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.1.2.4 REST OF THE WORLD NOSOCOMIAL PNEUMONIA MARKET, BY COUNTRY
9.5.2 RESPIRATORY INFECTIONS MARKET, BY REGION
9.5.2.1 NORTH AMERICA RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.5.2.2 EUROPE RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.5.2.3 ASIA-PACIFIC RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.5.2.4 REST OF THE WORLD RESPIRATORY INFECTIONS MARKET, BY COUNTRY
9.6 SKIN AND SOFT TISSUE INFECTIONS (SSTI)
9.6.1 GLOBAL SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.6.1.1 CELLULITIS MARKET, BY REGION
9.6.1.1.1 NORTH AMERICA CELLULITIS MARKET, BY COUNTRY
9.6.1.1.2 EUROPE CELLULITIS MARKET, BY COUNTRY
9.6.1.1.3 ASIA-PACIFIC CELLULITIS MARKET, BY COUNTRY
9.6.1.1.4 REST OF THE WORLD CELLULITIS MARKET, BY COUNTRY
9.6.1.2 ERYSIPELAS MARKET, BY REGION
9.6.1.2.1 NORTH AMERICA ERYSIPELAS MARKET, BY COUNTRY
9.6.1.2.2 EUROPE ERYSIPELAS MARKET, BY COUNTRY
9.6.1.2.3 ASIA-PACIFIC ERYSIPELAS MARKET, BY COUNTRY
9.6.1.2.4 REST OF THE WORLD ERYSIPELAS MARKET, BY COUNTRY
9.6.1.3 IMPETIGO MARKET, BY REGION
9.6.1.3.1 NORTH AMERICA IMPETIGO MARKET, BY COUNTRY
9.6.1.3.2 EUROPE IMPETIGO MARKET, BY COUNTRY
9.6.1.3.3 ASIA-PACIFIC IMPETIGO MARKET, BY COUNTRY
9.6.1.3.4 REST OF THE WORLD IMPETIGO MARKET, BY COUNTRY
9.6.1.4 OTHER SSTIS MARKET, BY REGION
9.6.1.4.1 NORTH AMERICA OTHER SSTIS MARKET, BY COUNTRY
9.6.1.4.2 EUROPE OTHER SSTIS MARKET, BY COUNTRY
9.6.1.4.3 ASIA-PACIFIC OTHER SSTIS MARKET, BY COUNTRY
9.6.1.4.4 REST OF THE WORLD OTHER SSTIS MARKET, BY COUNTRY
9.6.2 SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY REGION
9.6.2.1 NORTH AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.6.2.2 EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.6.2.3 ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.6.2.4 REST OF THE WORLD SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY COUNTRY
9.7 URINARY TRACT INFECTIONS (UTI)
9.7.1 GLOBAL URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.7.1.1 ACUTE UNCOMPLICATED UTI MARKET, BY REGION
9.7.1.1.1 NORTH AMERICA ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.1.2 EUROPE ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.1.3 ASIA-PACIFIC ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.1.4 REST OF THE WORLD ACUTE UNCOMPLICATED UTI MARKET, BY COUNTRY
9.7.1.2 CHRONIC/RECURRENT UTI MARKET, BY REGION
9.7.1.2.1 NORTH AMERICA CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.2.2 EUROPE CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.2.3 ASIA-PACIFIC CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.2.4 REST OF THE WORLD CHRONIC/RECURRENT UTI MARKET, BY COUNTRY
9.7.1.3 COMPLICATED UTI MARKET, BY REGION
9.7.1.3.1 NORTH AMERICA COMPLICATED UTI MARKET, BY COUNTRY
9.7.1.3.2 EUROPE COMPLICATED UTI MARKET, BY COUNTRY
9.7.1.3.3 ASIA-PACIFIC COMPLICATED UTI MARKET, BY COUNTRY
9.7.1.3.4 REST OF THE WORLD COMPLICATED UTI MARKET, BY COUNTRY
9.7.2 URINARY TRACT INFECTIONS (UTI) MARKET, BY REGION
9.7.2.1 NORTH AMERICA URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.7.2.2 EUROPE URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.7.2.3 ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.7.2.4 REST OF THE WORLD URINARY TRACT INFECTIONS (UTI) MARKET, BY COUNTRY
9.8 BLOODSTREAM INFECTIONS (BSI)
9.8.1 BLOODSTREAM INFECTIONS (BSI) MARKET, BY REGION
9.8.1.1 NORTH AMERICA BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.8.1.2 EUROPE BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.8.1.3 ASIA-PACIFIC BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.8.1.4 REST OF THE WORLD BLOODSTREAM INFECTIONS (BSI) MARKET, BY COUNTRY
9.9 OTHER INFECTIONS
9.9.1 GLOBAL OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
9.9.1.1 MENINGITIS MARKET, BY REGION
9.9.1.1.1 NORTH AMERICA MENINGITIS MARKET, BY COUNTRY
9.9.1.1.2 EUROPE MENINGITIS MARKET, BY COUNTRY
9.9.1.1.3 ASIA-PACIFIC MENINGITIS MARKET, BY COUNTRY
9.9.1.1.4 REST OF THE WORLD MENINGITIS MARKET, BY COUNTRY
9.9.1.2 OSTEOMYELITIS MARKET, BY REGION
9.9.1.2.1 NORTH AMERICA OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.2.2 EUROPE OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.2.3 ASIA-PACIFIC OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.2.4 REST OF THE WORLD OSTEOMYELITIS MARKET, BY COUNTRY
9.9.1.3 ENDOCARDITIS MARKET, BY REGION
9.9.1.3.1 NORTH AMERICA ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.3.2 EUROPE ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.3.3 ASIA-PACIFIC ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.3.4 REST OF THE WORLD ENDOCARDITIS MARKET, BY COUNTRY
9.9.1.4 OTHER RARE/OFF-LABEL USES MARKET, BY REGION
9.9.1.4.1 NORTH AMERICA OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.1.4.2 EUROPE OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.1.4.3 ASIA-PACIFIC OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.1.4.4 REST OF THE WORLD OTHER RARE/OFF-LABEL USES MARKET, BY COUNTRY
9.9.2 OTHER INFECTIONS MARKET, BY REGION
9.9.2.1 NORTH AMERICA OTHER INFECTIONS MARKET, BY COUNTRY
9.9.2.2 EUROPE OTHER INFECTIONS MARKET, BY COUNTRY
9.9.2.3 ASIA-PACIFIC OTHER INFECTIONS MARKET, BY COUNTRY
9.9.2.4 REST OF THE WORLD OTHER INFECTIONS MARKET, BY COUNTRY
10 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET BY END USER (HEALTHCARE SETTING)
10.1 OVERVIEW
10.2 ACADEMIC INSTITUTIONS
10.2.1 ACADEMIC INSTITUTIONS MARKET, BY REGION
10.2.1.1 NORTH AMERICA ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.2.1.2 EUROPE ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.2.1.3 ASIA-PACIFIC ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.2.1.4 REST OF THE WORLD ACADEMIC INSTITUTIONS MARKET, BY COUNTRY
10.3 CLINICS
10.3.1 CLINICS MARKET, BY REGION
10.3.1.1 NORTH AMERICA CLINICS MARKET, BY COUNTRY
10.3.1.2 EUROPE CLINICS MARKET, BY COUNTRY
10.3.1.3 ASIA-PACIFIC CLINICS MARKET, BY COUNTRY
10.3.1.4 REST OF THE WORLD CLINICS MARKET, BY COUNTRY
10.4 HOSPITALS
10.4.1 HOSPITALS MARKET, BY REGION
10.4.1.1 NORTH AMERICA HOSPITALS MARKET, BY COUNTRY
10.4.1.2 EUROPE HOSPITALS MARKET, BY COUNTRY
10.4.1.3 ASIA-PACIFIC HOSPITALS MARKET, BY COUNTRY
10.4.1.4 REST OF THE WORLD HOSPITALS MARKET, BY COUNTRY
10.5 RESEARCH LABORATORIES
10.5.1 RESEARCH LABORATORIES MARKET, BY REGION
10.5.1.1 NORTH AMERICA RESEARCH LABORATORIES MARKET, BY COUNTRY
10.5.1.2 EUROPE RESEARCH LABORATORIES MARKET, BY COUNTRY
10.5.1.3 ASIA-PACIFIC RESEARCH LABORATORIES MARKET, BY COUNTRY
10.5.1.4 REST OF THE WORLD RESEARCH LABORATORIES MARKET, BY COUNTRY
11 GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.1.1 NORTH AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.1.2 NORTH AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.2 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.2.1 NORTH AMERICA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.2.2 NORTH AMERICA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.3 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.3.1 NORTH AMERICA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.3.2 NORTH AMERICA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.4 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.1 NORTH AMERICA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.2 NORTH AMERICA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.3 NORTH AMERICA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.4 NORTH AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.5 NORTH AMERICA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.4.6 NORTH AMERICA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.5 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.2.6 NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.2.6.1 UNITED STATES
11.2.6.1.1 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.6.1.1.1 UNITED STATES INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.6.1.1.2 UNITED STATES BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.6.1.2 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.1.2.1 UNITED STATES ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.1.2.2 UNITED STATES PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.1.3 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.6.1.3.1 UNITED STATES ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.6.1.3.2 UNITED STATES PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.6.1.4 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.1 UNITED STATES GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.2 UNITED STATES INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.3 UNITED STATES RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.4 UNITED STATES SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.5 UNITED STATES URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.4.6 UNITED STATES OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.1.5 UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.2.6.2 CANADA
11.2.6.2.1 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.6.2.1.1 CANADA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.6.2.1.2 CANADA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.6.2.2 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.2.2.1 CANADA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.2.2.2 CANADA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.2.3 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.6.2.3.1 CANADA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.6.2.3.2 CANADA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.6.2.4 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.1 CANADA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.2 CANADA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.3 CANADA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.4 CANADA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.5 CANADA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.4.6 CANADA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.2.5 CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.2.6.3 MEXICO
11.2.6.3.1 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.2.6.3.1.1 MEXICO INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.2.6.3.1.2 MEXICO BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.2.6.3.2 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.3.2.1 MEXICO ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.3.2.2 MEXICO PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.2.6.3.3 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.2.6.3.3.1 MEXICO ADULT PATIENTS MARKET, BY PATIENT TYPE
11.2.6.3.3.2 MEXICO PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.2.6.3.4 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.1 MEXICO GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.2 MEXICO INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.3 MEXICO RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.4 MEXICO SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.5 MEXICO URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.4.6 MEXICO OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.2.6.3.5 MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3 EUROPE
11.3.1 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.1.1 EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.1.2 EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.2 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.2.1 EUROPE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.2.2 EUROPE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.3 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.3.1 EUROPE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.3.2 EUROPE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.4 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.1 EUROPE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.2 EUROPE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.3 EUROPE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.4 EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.5 EUROPE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.4.6 EUROPE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.5 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6 EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.3.6.1 GERMANY
11.3.6.1.1 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.1.1.1 GERMANY INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.1.1.2 GERMANY BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.1.2 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.1.2.1 GERMANY ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.1.2.2 GERMANY PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.1.3 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.1.3.1 GERMANY ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.1.3.2 GERMANY PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.1.4 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.1 GERMANY GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.2 GERMANY INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.3 GERMANY RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.4 GERMANY SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.5 GERMANY URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.4.6 GERMANY OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.1.5 GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.2 FRANCE
11.3.6.2.1 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.2.1.1 FRANCE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.2.1.2 FRANCE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.2.2 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.2.2.1 FRANCE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.2.2.2 FRANCE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.2.3 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.2.3.1 FRANCE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.2.3.2 FRANCE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.2.4 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.1 FRANCE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.2 FRANCE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.3 FRANCE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.4 FRANCE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.5 FRANCE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.4.6 FRANCE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.2.5 FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.3 ITALY
11.3.6.3.1 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.3.1.1 ITALY INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.3.1.2 ITALY BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.3.2 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.3.2.1 ITALY ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.3.2.2 ITALY PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.3.3 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.3.3.1 ITALY ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.3.3.2 ITALY PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.3.4 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.1 ITALY GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.2 ITALY INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.3 ITALY RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.4 ITALY SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.5 ITALY URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.4.6 ITALY OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.3.5 ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.4 SPAIN
11.3.6.4.1 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.4.1.1 SPAIN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.4.1.2 SPAIN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.4.2 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.4.2.1 SPAIN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.4.2.2 SPAIN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.4.3 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.4.3.1 SPAIN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.4.3.2 SPAIN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.4.4 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.1 SPAIN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.2 SPAIN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.3 SPAIN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.4 SPAIN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.5 SPAIN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.4.6 SPAIN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.4.5 SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.5 UNITED KINGDOM
11.3.6.5.1 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.5.1.1 UNITED KINGDOM INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.5.1.2 UNITED KINGDOM BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.5.2 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.5.2.1 UNITED KINGDOM ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.5.2.2 UNITED KINGDOM PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.5.3 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.5.3.1 UNITED KINGDOM ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.5.3.2 UNITED KINGDOM PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.5.4 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.1 UNITED KINGDOM GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.2 UNITED KINGDOM INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.3 UNITED KINGDOM RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.4 UNITED KINGDOM SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.5 UNITED KINGDOM URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.4.6 UNITED KINGDOM OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.5.5 UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.6 RUSSIA
11.3.6.6.1 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.6.1.1 RUSSIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.6.1.2 RUSSIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.6.2 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.6.2.1 RUSSIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.6.2.2 RUSSIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.6.3 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.6.3.1 RUSSIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.6.3.2 RUSSIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.6.4 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.1 RUSSIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.2 RUSSIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.3 RUSSIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.4 RUSSIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.5 RUSSIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.4.6 RUSSIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.6.5 RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.7 SWEDEN
11.3.6.7.1 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.7.1.1 SWEDEN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.7.1.2 SWEDEN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.7.2 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.7.2.1 SWEDEN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.7.2.2 SWEDEN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.7.3 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.7.3.1 SWEDEN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.7.3.2 SWEDEN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.7.4 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.1 SWEDEN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.2 SWEDEN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.3 SWEDEN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.4 SWEDEN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.5 SWEDEN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.4.6 SWEDEN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.7.5 SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.8 NORWAY
11.3.6.8.1 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.8.1.1 NORWAY INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.8.1.2 NORWAY BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.8.2 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.8.2.1 NORWAY ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.8.2.2 NORWAY PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.8.3 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.8.3.1 NORWAY ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.8.3.2 NORWAY PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.8.4 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.1 NORWAY GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.2 NORWAY INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.3 NORWAY RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.4 NORWAY SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.5 NORWAY URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.4.6 NORWAY OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.8.5 NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.9 DENMARK
11.3.6.9.1 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.9.1.1 DENMARK INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.9.1.2 DENMARK BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.9.2 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.9.2.1 DENMARK ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.9.2.2 DENMARK PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.9.3 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.9.3.1 DENMARK ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.9.3.2 DENMARK PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.9.4 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.1 DENMARK GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.2 DENMARK INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.3 DENMARK RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.4 DENMARK SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.5 DENMARK URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.4.6 DENMARK OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.9.5 DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.10 NETHERLANDS
11.3.6.10.1 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.10.1.1 NETHERLANDS INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.10.1.2 NETHERLANDS BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.10.2 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.10.2.1 NETHERLANDS ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.10.2.2 NETHERLANDS PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.10.3 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.10.3.1 NETHERLANDS ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.10.3.2 NETHERLANDS PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.10.4 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.1 NETHERLANDS GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.2 NETHERLANDS INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.3 NETHERLANDS RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.4 NETHERLANDS SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.5 NETHERLANDS URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.4.6 NETHERLANDS OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.10.5 NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.11 FINLAND
11.3.6.11.1 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.11.1.1 FINLAND INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.11.1.2 FINLAND BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.11.2 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.11.2.1 FINLAND ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.11.2.2 FINLAND PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.11.3 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.11.3.1 FINLAND ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.11.3.2 FINLAND PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.11.4 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.1 FINLAND GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.2 FINLAND INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.3 FINLAND RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.4 FINLAND SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.5 FINLAND URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.4.6 FINLAND OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.11.5 FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.3.6.12 REST OF EUROPE
11.3.6.12.1 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.3.6.12.1.1 REST OF EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.3.6.12.1.2 REST OF EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.3.6.12.2 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.12.2.1 REST OF EUROPE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.12.2.2 REST OF EUROPE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.3.6.12.3 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.3.6.12.3.1 REST OF EUROPE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.3.6.12.3.2 REST OF EUROPE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.3.6.12.4 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.1 REST OF EUROPE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.2 REST OF EUROPE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.3 REST OF EUROPE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.4 REST OF EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.5 REST OF EUROPE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.4.6 REST OF EUROPE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.3.6.12.5 REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4 ASIA-PACIFIC
11.4.1 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.1.1 ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.1.2 ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.2 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.2.1 ASIA-PACIFIC ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.2.2 ASIA-PACIFIC PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.3 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.3.1 ASIA-PACIFIC ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.3.2 ASIA-PACIFIC PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.4 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.1 ASIA-PACIFIC GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.2 ASIA-PACIFIC INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.3 ASIA-PACIFIC RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.4 ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.5 ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.4.6 ASIA-PACIFIC OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.5 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6 ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.4.6.1 AUSTRALIA
11.4.6.1.1 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.1.1.1 AUSTRALIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.1.1.2 AUSTRALIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.1.2 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.1.2.1 AUSTRALIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.1.2.2 AUSTRALIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.1.3 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.1.3.1 AUSTRALIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.1.3.2 AUSTRALIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.1.4 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.1 AUSTRALIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.2 AUSTRALIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.3 AUSTRALIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.4 AUSTRALIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.5 AUSTRALIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.4.6 AUSTRALIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.1.5 AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.2 CHINA
11.4.6.2.1 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.2.1.1 CHINA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.2.1.2 CHINA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.2.2 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.2.2.1 CHINA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.2.2.2 CHINA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.2.3 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.2.3.1 CHINA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.2.3.2 CHINA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.2.4 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.1 CHINA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.2 CHINA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.3 CHINA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.4 CHINA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.5 CHINA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.4.6 CHINA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.2.5 CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.3 INDIA
11.4.6.3.1 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.3.1.1 INDIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.3.1.2 INDIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.3.2 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.3.2.1 INDIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.3.2.2 INDIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.3.3 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.3.3.1 INDIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.3.3.2 INDIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.3.4 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.1 INDIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.2 INDIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.3 INDIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.4 INDIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.5 INDIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.4.6 INDIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.3.5 INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.4 JAPAN
11.4.6.4.1 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.4.1.1 JAPAN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.4.1.2 JAPAN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.4.2 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.4.2.1 JAPAN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.4.2.2 JAPAN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.4.3 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.4.3.1 JAPAN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.4.3.2 JAPAN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.4.4 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.1 JAPAN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.2 JAPAN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.3 JAPAN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.4 JAPAN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.5 JAPAN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.4.6 JAPAN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.4.5 JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.5 SOUTH KOREA
11.4.6.5.1 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.5.1.1 SOUTH KOREA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.5.1.2 SOUTH KOREA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.5.2 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.5.2.1 SOUTH KOREA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.5.2.2 SOUTH KOREA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.5.3 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.5.3.1 SOUTH KOREA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.5.3.2 SOUTH KOREA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.5.4 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.1 SOUTH KOREA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.2 SOUTH KOREA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.3 SOUTH KOREA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.4 SOUTH KOREA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.5 SOUTH KOREA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.4.6 SOUTH KOREA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.5.5 SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.6 INDONESIA
11.4.6.6.1 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.6.1.1 INDONESIA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.6.1.2 INDONESIA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.6.2 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.6.2.1 INDONESIA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.6.2.2 INDONESIA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.6.3 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.6.3.1 INDONESIA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.6.3.2 INDONESIA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.6.4 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.1 INDONESIA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.2 INDONESIA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.3 INDONESIA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.4 INDONESIA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.5 INDONESIA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.4.6 INDONESIA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.6.5 INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.7 SINGAPORE
11.4.6.7.1 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.7.1.1 SINGAPORE INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.7.1.2 SINGAPORE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.7.2 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.7.2.1 SINGAPORE ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.7.2.2 SINGAPORE PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.7.3 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.7.3.1 SINGAPORE ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.7.3.2 SINGAPORE PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.7.4 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.1 SINGAPORE GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.2 SINGAPORE INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.3 SINGAPORE RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.4 SINGAPORE SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.5 SINGAPORE URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.4.6 SINGAPORE OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.7.5 SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.8 TAIWAN
11.4.6.8.1 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.8.1.1 TAIWAN INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.8.1.2 TAIWAN BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.8.2 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.8.2.1 TAIWAN ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.8.2.2 TAIWAN PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.8.3 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.8.3.1 TAIWAN ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.8.3.2 TAIWAN PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.8.4 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.1 TAIWAN GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.2 TAIWAN INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.3 TAIWAN RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.4 TAIWAN SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.5 TAIWAN URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.4.6 TAIWAN OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.8.5 TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.9 THAILAND
11.4.6.9.1 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.9.1.1 THAILAND INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.9.1.2 THAILAND BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.9.2 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.9.2.1 THAILAND ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.9.2.2 THAILAND PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.9.3 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.9.3.1 THAILAND ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.9.3.2 THAILAND PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.9.4 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.1 THAILAND GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.2 THAILAND INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.3 THAILAND RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.4 THAILAND SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.5 THAILAND URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.4.6 THAILAND OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.9.5 THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.4.6.10 REST OF ASIA-PACIFIC
11.4.6.10.1 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.4.6.10.1.1 REST OF ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.4.6.10.1.2 REST OF ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.4.6.10.2 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.10.2.1 REST OF ASIA-PACIFIC ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.10.2.2 REST OF ASIA-PACIFIC PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.4.6.10.3 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.4.6.10.3.1 REST OF ASIA-PACIFIC ADULT PATIENTS MARKET, BY PATIENT TYPE
11.4.6.10.3.2 REST OF ASIA-PACIFIC PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.4.6.10.4 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.1 REST OF ASIA-PACIFIC GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.2 REST OF ASIA-PACIFIC INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.3 REST OF ASIA-PACIFIC RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.4 REST OF ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.5 REST OF ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.4.6 REST OF ASIA-PACIFIC OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.4.6.10.5 REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5 REST OF THE WORLD
11.5.1 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.1.1 REST OF THE WORLD INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.1.2 REST OF THE WORLD BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.2 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.2.1 REST OF THE WORLD ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.2.2 REST OF THE WORLD PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.3 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.3.1 REST OF THE WORLD ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.3.2 REST OF THE WORLD PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.4 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.1 REST OF THE WORLD GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.2 REST OF THE WORLD INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.3 REST OF THE WORLD RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.4 REST OF THE WORLD SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.5 REST OF THE WORLD URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.4.6 REST OF THE WORLD OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.5 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5.6 REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY COUNTRY
11.5.6.1 LATIN AMERICA
11.5.6.1.1 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.6.1.1.1 LATIN AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.6.1.1.2 LATIN AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.6.1.2 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.1.2.1 LATIN AMERICA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.1.2.2 LATIN AMERICA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.1.3 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.6.1.3.1 LATIN AMERICA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.6.1.3.2 LATIN AMERICA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.6.1.4 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.1 LATIN AMERICA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.2 LATIN AMERICA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.3 LATIN AMERICA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.4 LATIN AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.5 LATIN AMERICA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.4.6 LATIN AMERICA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.1.5 LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5.6.2 MIDDLE EAST
11.5.6.2.1 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.6.2.1.1 MIDDLE EAST INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.6.2.1.2 MIDDLE EAST BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.6.2.2 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.2.2.1 MIDDLE EAST ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.2.2.2 MIDDLE EAST PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.2.3 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.6.2.3.1 MIDDLE EAST ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.6.2.3.2 MIDDLE EAST PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.6.2.4 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.1 MIDDLE EAST GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.2 MIDDLE EAST INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.3 MIDDLE EAST RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.4 MIDDLE EAST SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.5 MIDDLE EAST URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.4.6 MIDDLE EAST OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.2.5 MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
11.5.6.3 AFRICA
11.5.6.3.1 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY TYPE
11.5.6.3.1.1 AFRICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET, BY TYPE
11.5.6.3.1.2 AFRICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET, BY TYPE
11.5.6.3.2 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.3.2.1 AFRICA ORAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.3.2.2 AFRICA PARENTERAL ADMINISTRATION MARKET, BY ROUTE OF ADMINISTRATION
11.5.6.3.3 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY PATIENT TYPE
11.5.6.3.3.1 AFRICA ADULT PATIENTS MARKET, BY PATIENT TYPE
11.5.6.3.3.2 AFRICA PEDIATRIC PATIENTS MARKET, BY PATIENT TYPE
11.5.6.3.4 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.1 AFRICA GYNECOLOGICAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.2 AFRICA INTRABDOMINAL INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.3 AFRICA RESPIRATORY INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.4 AFRICA SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.5 AFRICA URINARY TRACT INFECTIONS (UTI) MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.4.6 AFRICA OTHER INFECTIONS MARKET, BY APPLICATION/INDICATION (DISEASE LEVEL)
11.5.6.3.5 AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET, BY END USER (HEALTHCARE SETTING)
12 COMPANY PROFILES
12.1 AUROBINDO PHARMA
12.1.1 COMPANY OVERVIEW
12.1.2 COMPANY SNAPSHOT
12.1.3 OPERATING BUSINESS SEGMENTS
12.1.4 PRODUCT PORTFOLIO
12.1.5 BUSINESS PERFORMANCE
12.1.6 BUSINESS SEGMENTS
12.1.7 GEOGRAPHIC SEGMENTS
12.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.1.9 PRIMARY MARKET COMPETITORS
12.2 CIPLA INC.
12.2.1 COMPANY OVERVIEW
12.2.2 COMPANY SNAPSHOT
12.2.3 OPERATING BUSINESS SEGMENTS
12.2.4 PRODUCT PORTFOLIO
12.2.5 BUSINESS PERFORMANCE
12.2.6 BUSINESS SEGMENTS
12.2.7 GEOGRAPHIC SEGMENTS
12.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.2.9 PRIMARY MARKET COMPETITORS
12.3 DR. REDDY’S LABORATORIES LTD.
12.3.1 COMPANY OVERVIEW
12.3.2 COMPANY SNAPSHOT
12.3.3 OPERATING BUSINESS SEGMENTS
12.3.4 PRODUCT PORTFOLIO
12.3.5 BUSINESS PERFORMANCE
12.3.6 BUSINESS SEGMENTS
12.3.7 GEOGRAPHIC SEGMENTS
12.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.3.9 PRIMARY MARKET COMPETITORS
12.4 GLAXOSMITHKLINE PLC
12.4.1 COMPANY OVERVIEW
12.4.2 COMPANY SNAPSHOT
12.4.3 OPERATING BUSINESS SEGMENTS
12.4.4 PRODUCT PORTFOLIO
12.4.5 BUSINESS PERFORMANCE
12.4.6 BUSINESS SEGMENTS
12.4.7 GEOGRAPHIC SEGMENTS
12.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.4.9 PRIMARY MARKET COMPETITORS
12.5 HIKMA PHARMACEUTICALS PLC
12.5.1 COMPANY OVERVIEW
12.5.2 COMPANY SNAPSHOT
12.5.3 OPERATING BUSINESS SEGMENTS
12.5.4 PRODUCT PORTFOLIO
12.5.5 BUSINESS PERFORMANCE
12.5.6 BUSINESS SEGMENTS
12.5.7 GEOGRAPHIC SEGMENTS
12.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.5.9 PRIMARY MARKET COMPETITORS
12.6 LUPIN LTD.
12.6.1 COMPANY OVERVIEW
12.6.2 COMPANY SNAPSHOT
12.6.3 OPERATING BUSINESS SEGMENTS
12.6.4 PRODUCT PORTFOLIO
12.6.5 BUSINESS PERFORMANCE
12.6.6 BUSINESS SEGMENTS
12.6.7 GEOGRAPHIC SEGMENTS
12.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.6.9 PRIMARY MARKET COMPETITORS
12.7 MEIJI HOLDINGS CO. LTD.
12.7.1 COMPANY OVERVIEW
12.7.2 COMPANY SNAPSHOT
12.7.3 OPERATING BUSINESS SEGMENTS
12.7.4 PRODUCT PORTFOLIO
12.7.5 BUSINESS PERFORMANCE
12.7.6 BUSINESS SEGMENTS
12.7.7 GEOGRAPHIC SEGMENTS
12.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.7.9 PRIMARY MARKET COMPETITORS
12.8 MERCK & CO. INC.
12.8.1 COMPANY OVERVIEW
12.8.2 COMPANY SNAPSHOT
12.8.3 OPERATING BUSINESS SEGMENTS
12.8.4 PRODUCT PORTFOLIO
12.8.5 BUSINESS PERFORMANCE
12.8.6 BUSINESS SEGMENTS
12.8.7 GEOGRAPHIC SEGMENTS
12.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.8.9 PRIMARY MARKET COMPETITORS
12.9 PFIZER INC.
12.9.1 COMPANY OVERVIEW
12.9.2 COMPANY SNAPSHOT
12.9.3 OPERATING BUSINESS SEGMENTS
12.9.4 PRODUCT PORTFOLIO
12.9.5 BUSINESS PERFORMANCE
12.9.6 BUSINESS SEGMENTS
12.9.7 GEOGRAPHIC SEGMENTS
12.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.9.9 PRIMARY MARKET COMPETITORS
12.10 SANDOZ INTERNATIONAL GMBH (NOVARTIS)
12.10.1 COMPANY OVERVIEW
12.10.2 COMPANY SNAPSHOT
12.10.3 OPERATING BUSINESS SEGMENTS
12.10.4 PRODUCT PORTFOLIO
12.10.5 BUSINESS PERFORMANCE
12.10.6 BUSINESS SEGMENTS
12.10.7 GEOGRAPHIC SEGMENTS
12.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.10.9 PRIMARY MARKET COMPETITORS
12.11 SHIONOGI & CO., LTD.
12.11.1 COMPANY OVERVIEW
12.11.2 COMPANY SNAPSHOT
12.11.3 OPERATING BUSINESS SEGMENTS
12.11.4 PRODUCT PORTFOLIO
12.11.5 BUSINESS PERFORMANCE
12.11.6 BUSINESS SEGMENTS
12.11.7 GEOGRAPHIC SEGMENTS
12.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.11.9 PRIMARY MARKET COMPETITORS
12.12 SUN PHARMACEUTICAL INDUSTRIES LTD.
12.12.1 COMPANY OVERVIEW
12.12.2 COMPANY SNAPSHOT
12.12.3 OPERATING BUSINESS SEGMENTS
12.12.4 PRODUCT PORTFOLIO
12.12.5 BUSINESS PERFORMANCE
12.12.6 BUSINESS SEGMENTS
12.12.7 GEOGRAPHIC SEGMENTS
12.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.12.9 PRIMARY MARKET COMPETITORS
12.13 TAJ PHARMACEUTICALS LTD.
12.13.1 COMPANY OVERVIEW
12.13.2 COMPANY SNAPSHOT
12.13.3 OPERATING BUSINESS SEGMENTS
12.13.4 PRODUCT PORTFOLIO
12.13.5 BUSINESS PERFORMANCE
12.13.6 BUSINESS SEGMENTS
12.13.7 GEOGRAPHIC SEGMENTS
12.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.13.9 PRIMARY MARKET COMPETITORS
12.14 TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.14.1 COMPANY OVERVIEW
12.14.2 COMPANY SNAPSHOT
12.14.3 OPERATING BUSINESS SEGMENTS
12.14.4 PRODUCT PORTFOLIO
12.14.5 BUSINESS PERFORMANCE
12.14.6 BUSINESS SEGMENTS
12.14.7 GEOGRAPHIC SEGMENTS
12.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.14.9 PRIMARY MARKET COMPETITORS
12.15 TORRENT PHARMACEUTICALS LTD.
12.15.1 COMPANY OVERVIEW
12.15.2 COMPANY SNAPSHOT
12.15.3 OPERATING BUSINESS SEGMENTS
12.15.4 PRODUCT PORTFOLIO
12.15.5 BUSINESS PERFORMANCE
12.15.6 BUSINESS SEGMENTS
12.15.7 GEOGRAPHIC SEGMENTS
12.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.15.9 PRIMARY MARKET COMPETITORS
12.16 VIATRIS (FORMERLY MYLAN N.V.)
12.16.1 COMPANY OVERVIEW
12.16.2 COMPANY SNAPSHOT
12.16.3 OPERATING BUSINESS SEGMENTS
12.16.4 PRODUCT PORTFOLIO
12.16.5 BUSINESS PERFORMANCE
12.16.6 BUSINESS SEGMENTS
12.16.7 GEOGRAPHIC SEGMENTS
12.16.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.16.9 PRIMARY MARKET COMPETITORS
12.17 ZEELAB LABORATORIES LTD.
12.17.1 COMPANY OVERVIEW
12.17.2 COMPANY SNAPSHOT
12.17.3 OPERATING BUSINESS SEGMENTS
12.17.4 PRODUCT PORTFOLIO
12.17.5 BUSINESS PERFORMANCE
12.17.6 BUSINESS SEGMENTS
12.17.7 GEOGRAPHIC SEGMENTS
12.17.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.17.9 PRIMARY MARKET COMPETITORS
12.18 ZENTIVA GROUP B.V.
12.18.1 COMPANY OVERVIEW
12.18.2 COMPANY SNAPSHOT
12.18.3 OPERATING BUSINESS SEGMENTS
12.18.4 PRODUCT PORTFOLIO
12.18.5 BUSINESS PERFORMANCE
12.18.6 BUSINESS SEGMENTS
12.18.7 GEOGRAPHIC SEGMENTS
12.18.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.18.9 PRIMARY MARKET COMPETITORS
12.19 ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE)
12.19.1 COMPANY OVERVIEW
12.19.2 COMPANY SNAPSHOT
12.19.3 OPERATING BUSINESS SEGMENTS
12.19.4 PRODUCT PORTFOLIO
12.19.5 BUSINESS PERFORMANCE
12.19.6 BUSINESS SEGMENTS
12.19.7 GEOGRAPHIC SEGMENTS
12.19.8 KEY STRATEGIC MOVES AND DEVELOPMENT
12.19.9 PRIMARY MARKET COMPETITORS
LIST OF TABLES
TABLE 1. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 2. INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 3. NORTH AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 4. EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 5. ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 6. REST OF THE WORLD INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 7. BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 8. NORTH AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 9. EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 10. ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 11. REST OF THE WORLD BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 12. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 13. ORAL ADMINISTRATION MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 14. NORTH AMERICA ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 15. EUROPE ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 16. ASIA-PACIFIC ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 17. REST OF THE WORLD ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 18. PARENTERAL ADMINISTRATION MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 19. NORTH AMERICA PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 20. EUROPE PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 21. ASIA-PACIFIC PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 22. REST OF THE WORLD PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 23. OTHER ROUTES MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 24. NORTH AMERICA OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 25. EUROPE OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 26. ASIA-PACIFIC OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 27. REST OF THE WORLD OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 28. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 29. ADULT PATIENTS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 30. NORTH AMERICA ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 31. EUROPE ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 32. ASIA-PACIFIC ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 33. REST OF THE WORLD ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 34. PEDIATRIC PATIENTS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 35. NORTH AMERICA PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 36. EUROPE PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 37. ASIA-PACIFIC PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 38. REST OF THE WORLD PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 39. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 40. GYNECOLOGICAL INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 41. NORTH AMERICA GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 42. EUROPE GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 43. ASIA-PACIFIC GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 44. REST OF THE WORLD GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 45. INTRABDOMINAL INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 46. NORTH AMERICA INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 47. EUROPE INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 48. ASIA-PACIFIC INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 49. REST OF THE WORLD INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 50. INTRAOPERATIVE PROPHYLAXIS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 51. NORTH AMERICA INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 52. EUROPE INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 53. ASIA-PACIFIC INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 54. REST OF THE WORLD INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 55. RESPIRATORY INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 56. NORTH AMERICA RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 57. EUROPE RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 58. ASIA-PACIFIC RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 59. REST OF THE WORLD RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 60. SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 61. NORTH AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 62. EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 63. ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 64. REST OF THE WORLD SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 65. URINARY TRACT INFECTIONS (UTI) MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 66. NORTH AMERICA URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 67. EUROPE URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 68. ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 69. REST OF THE WORLD URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 70. BLOODSTREAM INFECTIONS (BSI) MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 71. NORTH AMERICA BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 72. EUROPE BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 73. ASIA-PACIFIC BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 74. REST OF THE WORLD BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 75. OTHER INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 76. NORTH AMERICA OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 77. EUROPE OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 78. ASIA-PACIFIC OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 79. REST OF THE WORLD OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 80. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 81. ACADEMIC INSTITUTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 82. NORTH AMERICA ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 83. EUROPE ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 84. ASIA-PACIFIC ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 85. REST OF THE WORLD ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 86. CLINICS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 87. NORTH AMERICA CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 88. EUROPE CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 89. ASIA-PACIFIC CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 90. REST OF THE WORLD CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 91. HOSPITALS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 92. NORTH AMERICA HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 93. EUROPE HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 94. ASIA-PACIFIC HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 95. REST OF THE WORLD HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 96. RESEARCH LABORATORIES MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 97. NORTH AMERICA RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 98. EUROPE RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 99. ASIA-PACIFIC RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 100. REST OF THE WORLD RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
TABLE 101. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
TABLE 102. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 103. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 104. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 105. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 106. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 107. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 108. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 109. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 110. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 111. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 112. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 113. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 114. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 115. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 116. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 117. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 118. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 119. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 120. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 121. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 122. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 123. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 124. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 125. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 126. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 127. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 128. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 129. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 130. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 131. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 132. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 133. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 134. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 135. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 136. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 137. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 138. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 139. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 140. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 141. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 142. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 143. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 144. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 145. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 146. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 147. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 148. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 149. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 150. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 151. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 152. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 153. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 154. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 155. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 156. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 157. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 158. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 159. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 160. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 161. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 162. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 163. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 164. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 165. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 166. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 167. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 168. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 169. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 170. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 171. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 172. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 173. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 174. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 175. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 176. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 177. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 178. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 179. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 180. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 181. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 182. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 183. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 184. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 185. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 186. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 187. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 188. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 189. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 190. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 191. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 192. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 193. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 194. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 195. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 196. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 197. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 198. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 199. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 200. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 201. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 202. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 203. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 204. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 205. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 206. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 207. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 208. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 209. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 210. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 211. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 212. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 213. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 214. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 215. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 216. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 217. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 218. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 219. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 220. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 221. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 222. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 223. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 224. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 225. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 226. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 227. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 228. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 229. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 230. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 231. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 232. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 233. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 234. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 235. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 236. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 237. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 238. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 239. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 240. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 241. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 242. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 243. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 244. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 245. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 246. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 247. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 248. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 249. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 250. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 251. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 252. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 253. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 254. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 255. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 256. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 257. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
TABLE 258. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
TABLE 259. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
TABLE 260. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
TABLE 261. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
TABLE 262. AUROBINDO PHARMA: COMPANY SNAPSHOT
TABLE 263. AUROBINDO PHARMA: OPERATING BUSINESS SEGMENTS
TABLE 264. AUROBINDO PHARMA: PRODUCT PORTFOLIO
TABLE 265. AUROBINDO PHARMA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 266. AUROBINDO PHARMA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 267. AUROBINDO PHARMA: KEY STRATERGY
TABLE 268. CIPLA INC.: COMPANY SNAPSHOT
TABLE 269. CIPLA INC.: OPERATING BUSINESS SEGMENTS
TABLE 270. CIPLA INC.: PRODUCT PORTFOLIO
TABLE 271. CIPLA INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 272. CIPLA INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 273. CIPLA INC.: KEY STRATERGY
TABLE 274. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 275. DR. REDDY’S LABORATORIES LTD.: OPERATING BUSINESS SEGMENTS
TABLE 276. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 277. DR. REDDY’S LABORATORIES LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 278. DR. REDDY’S LABORATORIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 279. DR. REDDY’S LABORATORIES LTD.: KEY STRATERGY
TABLE 280. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 281. GLAXOSMITHKLINE PLC: OPERATING BUSINESS SEGMENTS
TABLE 282. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 283. GLAXOSMITHKLINE PLC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 284. GLAXOSMITHKLINE PLC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 285. GLAXOSMITHKLINE PLC: KEY STRATERGY
TABLE 286. HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 287. HIKMA PHARMACEUTICALS PLC: OPERATING BUSINESS SEGMENTS
TABLE 288. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 289. HIKMA PHARMACEUTICALS PLC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 290. HIKMA PHARMACEUTICALS PLC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 291. HIKMA PHARMACEUTICALS PLC: KEY STRATERGY
TABLE 292. LUPIN LTD.: COMPANY SNAPSHOT
TABLE 293. LUPIN LTD.: OPERATING BUSINESS SEGMENTS
TABLE 294. LUPIN LTD.: PRODUCT PORTFOLIO
TABLE 295. LUPIN LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 296. LUPIN LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 297. LUPIN LTD.: KEY STRATERGY
TABLE 298. MEIJI HOLDINGS CO. LTD.: COMPANY SNAPSHOT
TABLE 299. MEIJI HOLDINGS CO. LTD.: OPERATING BUSINESS SEGMENTS
TABLE 300. MEIJI HOLDINGS CO. LTD.: PRODUCT PORTFOLIO
TABLE 301. MEIJI HOLDINGS CO. LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 302. MEIJI HOLDINGS CO. LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 303. MEIJI HOLDINGS CO. LTD.: KEY STRATERGY
TABLE 304. MERCK & CO. INC.: COMPANY SNAPSHOT
TABLE 305. MERCK & CO. INC.: OPERATING BUSINESS SEGMENTS
TABLE 306. MERCK & CO. INC.: PRODUCT PORTFOLIO
TABLE 307. MERCK & CO. INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 308. MERCK & CO. INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 309. MERCK & CO. INC.: KEY STRATERGY
TABLE 310. PFIZER INC.: COMPANY SNAPSHOT
TABLE 311. PFIZER INC.: OPERATING BUSINESS SEGMENTS
TABLE 312. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 313. PFIZER INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 314. PFIZER INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 315. PFIZER INC.: KEY STRATERGY
TABLE 316. SANDOZ INTERNATIONAL GMBH (NOVARTIS): COMPANY SNAPSHOT
TABLE 317. SANDOZ INTERNATIONAL GMBH (NOVARTIS): OPERATING BUSINESS SEGMENTS
TABLE 318. SANDOZ INTERNATIONAL GMBH (NOVARTIS): PRODUCT PORTFOLIO
TABLE 319. SANDOZ INTERNATIONAL GMBH (NOVARTIS): SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 320. SANDOZ INTERNATIONAL GMBH (NOVARTIS): SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 321. SANDOZ INTERNATIONAL GMBH (NOVARTIS): KEY STRATERGY
TABLE 322. SHIONOGI & CO., LTD.: COMPANY SNAPSHOT
TABLE 323. SHIONOGI & CO., LTD.: OPERATING BUSINESS SEGMENTS
TABLE 324. SHIONOGI & CO., LTD.: PRODUCT PORTFOLIO
TABLE 325. SHIONOGI & CO., LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 326. SHIONOGI & CO., LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 327. SHIONOGI & CO., LTD.: KEY STRATERGY
TABLE 328. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 329. SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS
TABLE 330. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 331. SUN PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 332. SUN PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 333. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY
TABLE 334. TAJ PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
TABLE 335. TAJ PHARMACEUTICALS LTD.: OPERATING BUSINESS SEGMENTS
TABLE 336. TAJ PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 337. TAJ PHARMACEUTICALS LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 338. TAJ PHARMACEUTICALS LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 339. TAJ PHARMACEUTICALS LTD.: KEY STRATERGY
TABLE 340. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 341. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS
TABLE 342. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 343. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 344. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 345. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY
TABLE 346. TORRENT PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
TABLE 347. TORRENT PHARMACEUTICALS LTD.: OPERATING BUSINESS SEGMENTS
TABLE 348. TORRENT PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 349. TORRENT PHARMACEUTICALS LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 350. TORRENT PHARMACEUTICALS LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 351. TORRENT PHARMACEUTICALS LTD.: KEY STRATERGY
TABLE 352. VIATRIS (FORMERLY MYLAN N.V.): COMPANY SNAPSHOT
TABLE 353. VIATRIS (FORMERLY MYLAN N.V.): OPERATING BUSINESS SEGMENTS
TABLE 354. VIATRIS (FORMERLY MYLAN N.V.): PRODUCT PORTFOLIO
TABLE 355. VIATRIS (FORMERLY MYLAN N.V.): SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 356. VIATRIS (FORMERLY MYLAN N.V.): SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 357. VIATRIS (FORMERLY MYLAN N.V.): KEY STRATERGY
TABLE 358. ZEELAB LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 359. ZEELAB LABORATORIES LTD.: OPERATING BUSINESS SEGMENTS
TABLE 360. ZEELAB LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 361. ZEELAB LABORATORIES LTD.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 362. ZEELAB LABORATORIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 363. ZEELAB LABORATORIES LTD.: KEY STRATERGY
TABLE 364. ZENTIVA GROUP B.V.: COMPANY SNAPSHOT
TABLE 365. ZENTIVA GROUP B.V.: OPERATING BUSINESS SEGMENTS
TABLE 366. ZENTIVA GROUP B.V.: PRODUCT PORTFOLIO
TABLE 367. ZENTIVA GROUP B.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 368. ZENTIVA GROUP B.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 369. ZENTIVA GROUP B.V.: KEY STRATERGY
TABLE 370. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): COMPANY SNAPSHOT
TABLE 371. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): OPERATING BUSINESS SEGMENTS
TABLE 372. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): PRODUCT PORTFOLIO
TABLE 373. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 374. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 375. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): KEY STRATERGY
LIST OF FIGURES
FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE, 2024-2030, (BILLION USD)
FIGURE 7. INDIVIDUAL BETA-LACTAM ANTIBIOTICS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 8. NORTH AMERICA INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 9. EUROPE INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 10. ASIA-PACIFIC INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 11. REST OF THE WORLD INDIVIDUAL BETA-LACTAM ANTIBIOTICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 12. BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 13. NORTH AMERICA BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 14. EUROPE BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 15. ASIA-PACIFIC BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 16. REST OF THE WORLD BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 17. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2024-2030, (BILLION USD)
FIGURE 18. ORAL ADMINISTRATION MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 19. NORTH AMERICA ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 20. EUROPE ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 21. ASIA-PACIFIC ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 22. REST OF THE WORLD ORAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 23. PARENTERAL ADMINISTRATION MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 24. NORTH AMERICA PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 25. EUROPE PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 26. ASIA-PACIFIC PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 27. REST OF THE WORLD PARENTERAL ADMINISTRATION, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 28. OTHER ROUTES MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 29. NORTH AMERICA OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 30. EUROPE OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 31. ASIA-PACIFIC OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 32. REST OF THE WORLD OTHER ROUTES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 33. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE, 2024-2030, (BILLION USD)
FIGURE 34. ADULT PATIENTS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 35. NORTH AMERICA ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 36. EUROPE ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 37. ASIA-PACIFIC ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 38. REST OF THE WORLD ADULT PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 39. PEDIATRIC PATIENTS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 40. NORTH AMERICA PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 41. EUROPE PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 42. ASIA-PACIFIC PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 43. REST OF THE WORLD PEDIATRIC PATIENTS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 44. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL), 2024-2030, (BILLION USD)
FIGURE 45. GYNECOLOGICAL INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 46. NORTH AMERICA GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 47. EUROPE GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 48. ASIA-PACIFIC GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 49. REST OF THE WORLD GYNECOLOGICAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 50. INTRABDOMINAL INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 51. NORTH AMERICA INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 52. EUROPE INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 53. ASIA-PACIFIC INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 54. REST OF THE WORLD INTRABDOMINAL INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 55. INTRAOPERATIVE PROPHYLAXIS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 56. NORTH AMERICA INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 57. EUROPE INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 58. ASIA-PACIFIC INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 59. REST OF THE WORLD INTRAOPERATIVE PROPHYLAXIS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 60. RESPIRATORY INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 61. NORTH AMERICA RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 62. EUROPE RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 63. ASIA-PACIFIC RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 64. REST OF THE WORLD RESPIRATORY INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 65. SKIN AND SOFT TISSUE INFECTIONS (SSTI) MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 66. NORTH AMERICA SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 67. EUROPE SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 68. ASIA-PACIFIC SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 69. REST OF THE WORLD SKIN AND SOFT TISSUE INFECTIONS (SSTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 70. URINARY TRACT INFECTIONS (UTI) MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 71. NORTH AMERICA URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 72. EUROPE URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 73. ASIA-PACIFIC URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 74. REST OF THE WORLD URINARY TRACT INFECTIONS (UTI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 75. BLOODSTREAM INFECTIONS (BSI) MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 76. NORTH AMERICA BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 77. EUROPE BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 78. ASIA-PACIFIC BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 79. REST OF THE WORLD BLOODSTREAM INFECTIONS (BSI), MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 80. OTHER INFECTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 81. NORTH AMERICA OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 82. EUROPE OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 83. ASIA-PACIFIC OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 84. REST OF THE WORLD OTHER INFECTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 85. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING), 2024-2030, (BILLION USD)
FIGURE 86. ACADEMIC INSTITUTIONS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 87. NORTH AMERICA ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 88. EUROPE ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 89. ASIA-PACIFIC ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 90. REST OF THE WORLD ACADEMIC INSTITUTIONS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 91. CLINICS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 92. NORTH AMERICA CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 93. EUROPE CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 94. ASIA-PACIFIC CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 95. REST OF THE WORLD CLINICS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 96. HOSPITALS MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 97. NORTH AMERICA HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 98. EUROPE HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 99. ASIA-PACIFIC HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 100. REST OF THE WORLD HOSPITALS, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 101. RESEARCH LABORATORIES MARKET VALUE, BY REGION, 2024-2030, (BILLION USD)
FIGURE 102. NORTH AMERICA RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 103. EUROPE RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 104. ASIA-PACIFIC RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 105. REST OF THE WORLD RESEARCH LABORATORIES, MARKET VALUE, BY COUNTRY, 2024-2030, (BILLION USD)
FIGURE 106. GLOBAL BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY REGION 2024-2030, (BILLION USD)
FIGURE 107. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 108. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 109. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 110. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 111. NORTH AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 112. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 113. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 114. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 115. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 116. UNITED STATES BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 117. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 118. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 119. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 120. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 121. CANADA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 122. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 123. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 124. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 125. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 126. MEXICO BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 127. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 128. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 129. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 130. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 131. EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 132. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 133. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 134. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 135. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 136. GERMANY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 137. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 138. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 139. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 140. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 141. FRANCE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 142. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 143. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 144. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 145. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 146. ITALY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 147. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 148. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 149. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 150. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 151. SPAIN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 152. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 153. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 154. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 155. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 156. UNITED KINGDOM BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 157. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 158. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 159. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 160. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 161. RUSSIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 162. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 163. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 164. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 165. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 166. SWEDEN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 167. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 168. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 169. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 170. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 171. NORWAY BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 172. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 173. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 174. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 175. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 176. DENMARK BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 177. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 178. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 179. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 180. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 181. NETHERLANDS BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 182. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 183. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 184. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 185. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 186. FINLAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 187. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 188. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 189. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 190. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 191. REST OF EUROPE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 192. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 193. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 194. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 195. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 196. ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 197. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 198. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 199. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 200. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 201. AUSTRALIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 202. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 203. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 204. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 205. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 206. CHINA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 207. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 208. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 209. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 210. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 211. INDIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 212. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 213. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 214. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 215. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 216. JAPAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 217. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 218. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 219. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 220. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 221. SOUTH KOREA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 222. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 223. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 224. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 225. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 226. INDONESIA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 227. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 228. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 229. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 230. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 231. SINGAPORE BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 232. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 233. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 234. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 235. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 236. TAIWAN BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 237. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 238. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 239. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 240. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 241. THAILAND BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 242. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 243. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 244. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 245. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 246. REST OF ASIA-PACIFIC BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 247. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 248. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 249. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 250. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 251. REST OF THE WORLD BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 252. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 253. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 254. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 255. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 256. LATIN AMERICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 257. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 258. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 259. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 260. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 261. MIDDLE EAST BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 262. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY TYPE 2024-2030, (BILLION USD)
FIGURE 263. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY ROUTE OF ADMINISTRATION 2024-2030, (BILLION USD)
FIGURE 264. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY PATIENT TYPE 2024-2030, (BILLION USD)
FIGURE 265. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY APPLICATION/INDICATION (DISEASE LEVEL) 2024-2030, (BILLION USD)
FIGURE 266. AFRICA BETA-LACTAM AND BETA-LACTAMASE INHIBITORS MARKET VALUE, BY END USER (HEALTHCARE SETTING) 2024-2030, (BILLION USD)
FIGURE 267. AUROBINDO PHARMA: NET SALES, (2022-2024)
FIGURE 268. AUROBINDO PHARMA: PRIMARY MARKET COMPETITORS
FIGURE 269. CIPLA INC.: NET SALES, (2022-2024)
FIGURE 270. CIPLA INC.: PRIMARY MARKET COMPETITORS
FIGURE 271. DR. REDDY’S LABORATORIES LTD.: NET SALES, (2022-2024)
FIGURE 272. DR. REDDY’S LABORATORIES LTD.: PRIMARY MARKET COMPETITORS
FIGURE 273. GLAXOSMITHKLINE PLC: NET SALES, (2022-2024)
FIGURE 274. GLAXOSMITHKLINE PLC: PRIMARY MARKET COMPETITORS
FIGURE 275. HIKMA PHARMACEUTICALS PLC: NET SALES, (2022-2024)
FIGURE 276. HIKMA PHARMACEUTICALS PLC: PRIMARY MARKET COMPETITORS
FIGURE 277. LUPIN LTD.: NET SALES, (2022-2024)
FIGURE 278. LUPIN LTD.: PRIMARY MARKET COMPETITORS
FIGURE 279. MEIJI HOLDINGS CO. LTD.: NET SALES, (2022-2024)
FIGURE 280. MEIJI HOLDINGS CO. LTD.: PRIMARY MARKET COMPETITORS
FIGURE 281. MERCK & CO. INC.: NET SALES, (2022-2024)
FIGURE 282. MERCK & CO. INC.: PRIMARY MARKET COMPETITORS
FIGURE 283. PFIZER INC.: NET SALES, (2022-2024)
FIGURE 284. PFIZER INC.: PRIMARY MARKET COMPETITORS
FIGURE 285. SANDOZ INTERNATIONAL GMBH (NOVARTIS): NET SALES, (2022-2024)
FIGURE 286. SANDOZ INTERNATIONAL GMBH (NOVARTIS): PRIMARY MARKET COMPETITORS
FIGURE 287. SHIONOGI & CO., LTD.: NET SALES, (2022-2024)
FIGURE 288. SHIONOGI & CO., LTD.: PRIMARY MARKET COMPETITORS
FIGURE 289. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2022-2024)
FIGURE 290. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS
FIGURE 291. TAJ PHARMACEUTICALS LTD.: NET SALES, (2022-2024)
FIGURE 292. TAJ PHARMACEUTICALS LTD.: PRIMARY MARKET COMPETITORS
FIGURE 293. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2022-2024)
FIGURE 294. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS
FIGURE 295. TORRENT PHARMACEUTICALS LTD.: NET SALES, (2022-2024)
FIGURE 296. TORRENT PHARMACEUTICALS LTD.: PRIMARY MARKET COMPETITORS
FIGURE 297. VIATRIS (FORMERLY MYLAN N.V.): NET SALES, (2022-2024)
FIGURE 298. VIATRIS (FORMERLY MYLAN N.V.): PRIMARY MARKET COMPETITORS
FIGURE 299. ZEELAB LABORATORIES LTD.: NET SALES, (2022-2024)
FIGURE 300. ZEELAB LABORATORIES LTD.: PRIMARY MARKET COMPETITORS
FIGURE 301. ZENTIVA GROUP B.V.: NET SALES, (2022-2024)
FIGURE 302. ZENTIVA GROUP B.V.: PRIMARY MARKET COMPETITORS
FIGURE 303. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): NET SALES, (2022-2024)
FIGURE 304. ZYDUS LIFESCIENCES LIMITED (CADILA HEALTHCARE): PRIMARY MARKET COMPETITORS
At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.
Research Landscape
We navigate the world of research with two primary approaches:
Qualitative Approach
Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.
Quantitative Research
In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.
Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.
Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.
Our Specialized Toolbox for Industry-Specific Market Research
We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:
Information Procurement
The stage entails acquiring market data or relevant information through various sources and methodologies.
Market Research Approach
We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.
Porters Five Forces Analysis
We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.
SWOT Analysis
We conduct SWOT analysis to understand market trends, identify potential threats, capitalize on opportunities, and assess our strengths and weaknesses.
Forecasting
We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.
Frequently Asked Questions
Speak to Our Analyst
Related Report
Related Blogs
What’s Shaping the Future of Immunoassays in Latin America?
According to the latest report published by the Next Move Strategy Consulting, t...
Innovations in Pharma Isolators: What’s Next?
Introduction Pharmaceutical Isolators, frequently referred to as containment...
Why Early Toxicity Testing Matters in Pharma
Introduction New drug development is a complex and highly regulated process that requires extensive testing to ensure their saf...
Download Sample
ReportYour Response Will be sent
Please provide your company email address for a faster response
Type Of License
Features |
|
|
|
|
|||||
|---|---|---|---|---|---|---|---|---|---|
|
Single User
|
Multi User
|
Enterprise User
|
Data Pack
|
||||||
|
US $ 3,975
|
US $ 4,975
|
US $ 6,975
|
US $ 2,975
|
||||||
|
1 user only
|
5 users
|
Unlimited access within the Organization
|
1 user only
|
||||||
|
Free Customization |
20 hours |
40 hours |
>60 hours |
NA |
|||||
|
Duration Of Free Analyst Support |
3 months post purchase |
6 months post purchase |
12 months post purchase |
NA |
|||||
|
Direct Access to the Analyst Team Through Calls / Email |
|
|
|
|
|||||
|
Deliverable Format |
|
|
|
|
|
||||
|
|
|
|
|
|
|||||
|
Discount on Your Next Purchase |
No Discount |
15% |
20% |
No Discount |
|||||
|
Permission to Print the Report |
|
|
|
|
|||||
